Final Program
3rd World Psoriasis & Psoriatic Arthritis Conference 2012

“Psoriasis – a global health challenge”
June 27–July 1, 2012 in Stockholm, Sweden
Conference mission

To impart current scientific and clinical care information about psoriasis and psoriatic arthritis to medical professionals, industry representatives and patient associations so they can collaborate to develop an international agenda to improve the understanding of psoriasis and psoriatic arthritis and access to care throughout the world.

Conference Objectives

- Bring medical professionals, industry representatives and national psoriasis association representatives from around the world together to examine current information about psoriasis and psoriatic arthritis.
- Encourage collaboration on developing future research and advocacy initiatives.
- Increase the global recognition of the seriousness of these diseases.
- Improve the quality of life of people who have psoriasis and psoriatic arthritis.
- Develop a broader international perspective of psoriasis and psoriatic arthritis.
- Increase medical professionals’ awareness of the value of nonprofit psoriasis associations, the role they play in assisting the medical communities and the value in supporting their efforts.
- Build partnerships with the medical professionals, researchers and the pharmaceutical/biotechnology industry.

Patron of the 3rd World Psoriasis & Psoriatic Arthritis Conference

His Majesty King Carl Gustav
## Content

Welcome

– IFPA President  
– Scientific Executive Committee

Committees

Contact and Conference information

Scientific Program

Social Program

Hotels and social event locations – map

Stockholm Waterfront Congress Centre

General Information

Stockholm and Sweden

Abstract Titles
Dear Friends,

In 2012 the International Federation of Psoriasis Associations (IFPA) will be holding the World Psoriasis & Psoriatic Conference in Stockholm for the third time, in cooperation with leading dermatologists and rheumatologists. The purpose of the conference is to elucidate the disease from a number of scientific aspects. At the first conference, in 2006, the focus was on clarifying the connection between psoriasis of the skin and psoriatic arthritis. At the second conference, in 2009, we moved on to present an aggregated picture of psoriasis as a complex, chronic, inflammatory disease that can affect several of the body’s organs through a number of co-morbidities.

For this upcoming conference we have even further deepened the cooperation between IFPA and the medical profession, and a number of new areas will be covered which will improve the understanding and care of psoriasis patients, such as the psychosocial impact on quality of life.

The scientific program will also, as before, be strongly influenced by IFPA’s worldwide member survey, to ensure that the patient’s perspective is included. As with the 2009 conference, there will also be special seminars and side tracks for nurses, allied health professionals and others who have a most important role in the care of psoriasis patients. This complementary program is arranged in cooperation with the International Skin care Nursing Group (ISNG).

Welcome to the 3rd World Psoriasis & Psoriatic Arthritis Conference and to the brand-new Stockholm Waterfront Congress Centre!

Yours sincerely,

Lars Ettarp
President of IFPA

Dear Colleagues, Ladies and Gentlemen,

Our understanding of the spectrum of psoriatic disease has made considerable strides since the last World Psoriasis & Psoriatic Arthritis Conference, held in Stockholm in 2009. New treatments are being developed, new insights have been obtained into the pathogenesis and clinical diagnosis, and the recognition of psoriasis as a noncommunicable disease with a great disease burden has further advanced. The previous two conferences, in 2006 and 2009, were very successful in allowing researchers, clinicians and patients to keep pace with this progress, and reinforced the need to continue this type of interaction.

The 3rd World Psoriasis & Psoriatic Arthritis Conference, to be held on June 27 to July 1, 2012, will provide us with the opportunity to address and discuss a broad spectrum of topics related to psoriatic disease. Organized by the International Federation of Psoriasis Associations, IFPA, the conference will take place in Stockholm in a brand-new congress venue, Stockholm Waterfront Congress Centre. Based on surveys among the national psoriasis patient organisations, and with the support from our colleagues on the scientific programme committee, we have developed a conference agenda with plenary lectures given by recognized experts in their field. This will ensure that relevant issues are being addressed with much practical expertise at the highest possible scientific level. Sponsored lunch seminars and satellite symposia will provide further information relevant to the clinical care and quality of life of psoriasis patients.

We are confident that with this programme we will be able to provide a lively platform for continuing medical education and scientific discussion related to psoriatic disease while allowing us all the opportunity to have open discussions with our colleagues and patients from around the world.

We look forward to seeing you in the beautiful city of Stockholm.

Yours sincerely,

Alan Menter
President of the 3rd World Psoriasis & Psoriatic Arthritis Conference
Chairman of the Scientific Executive Committee

Dafna Gladman
Co-chair of the Scientific Executive Committee

Jörg Prinz
Co-chair of the Scientific Executive Committee

Lars Ettarp
President of IFPA
Committees

Scientific Executive Committee
Alan Menter, Chairman
Dafna Gladman, Co-Chair
Jörg Prinz, Co-Chair

Scientific Program Committee
Hervé Bachelez
Jonathan Barker
Kenneth Gordon
Philip Helliwell
Arthur Kavanaugh
Alexa Kimball
Peter Nash
Proton Rahman

IFPA Scientific Advisory Board
Jörg Prinz
Peter van de Kerkhof
Mark Lebwohl
Philip Mease
Christopher Ritchlin
Mona Ståhle

Organizing Committee
Chairman: Joachim Barth
IFPA Executive Committee
IFPA Secretariat

Council of Scientific Advisors
Edgardo Chouela
Enno Christophers

Contact and Conference information

Conference organizer
Congrex Sweden AB
Phone: +46 8 459 66 00
Fax: + 46 8 661 91 25
E-mail: psoriasis2012@congrex.com
www.congrex.com

IFPA Secretariat
Box 5173
SE-121 18 Johanneshov
SWEDEN
Phone: +46 8 556 109 14
Fax: +46 8 556 109 19
E-mail: ifpa@pso.se
www.ifpa-psso.org
http://ifpaworldconference.com

Conference venue
Stockholm Waterfront Congress Centre
Nils Ericsons Plan 4
Stockholm
Phone: +46 8 5050 6000
www.stockholmwaterfront.com

Commercial exhibition and poster exhibition
Commercial exhibition open for access by medical professionals.
Thursday, 28 June 08.00 – 17.45
Friday, 29 June 07.30 – 17.45
Saturday, 30 June 07.30 – 17.15

Registration
For questions about the social program, payment or accommodations please contact the registration desk. Please see page 15 to view the map including the official hotels.

The registration fee for participants includes
• Admission to the conference 28-30 June
• Conference documentation
• Coffee/tea
• Conference reception, June 27 (if registered)
• Reception at Stockholm City Hall, June 28 (if registered)
• Conference dinner at subsidized rate (if registered)

The registration fee for accompanying persons includes
• Conference reception, June 27 (if registered)
• Reception at Stockholm City Hall, June 28 (if registered)
• Conference dinner at subsidized rate, June 29 (if registered)

Conference opening hours
Registration desk and general information desk
Wednesday, 27 June 18.00 – 20.00
Thursday, 28 June 07.30 – 18.00
Friday, 29 June 07.00 – 19.00
Saturday, 30 June 07.00 – 17.00

Speakers’ preview room
Wednesday, June 27 18.00 – 20.00
Thursday, June 28 07.30 – 18.00
Friday, June 29 07.00 – 19.00
Saturday, June 30 07.00 – 17.00

Foto: Ola Eriksson/imagebank.sweden.se
# Scientific Program

<table>
<thead>
<tr>
<th>Time</th>
<th>GENERAL PROGRAM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Pre-Conference meetings</strong></td>
</tr>
<tr>
<td></td>
<td>Meetings of international research consortia and subcommittees</td>
</tr>
<tr>
<td>18.00 – 20.00</td>
<td>Registration for the conference opens at the Stockholm Waterfront Congress Centre</td>
</tr>
<tr>
<td>18.00 – 19.00</td>
<td>Conference reception open for all delegates at the conference venue, floor 5</td>
</tr>
<tr>
<td>19.00 – 20.00</td>
<td>Welcome program (see page 13 for more information)</td>
</tr>
</tbody>
</table>

## Wednesday June 27

### Thursday June 28

<table>
<thead>
<tr>
<th>Time</th>
<th>Registration opens</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th><strong>Opening ceremony</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>08.15</td>
<td><strong>Plenary 1: Psoriatic disease, skin and joint pathogenesis</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Jörg Prinz, Dafna Gladman</td>
</tr>
<tr>
<td>08.40 – 10.00</td>
<td>Molecular pathways to psoriatic skin inflammation</td>
</tr>
<tr>
<td></td>
<td>Speaker: James Krueger</td>
</tr>
<tr>
<td>09.20 – 10.00</td>
<td>Mechanisms of bone formation and destruction in psoriatic arthritis</td>
</tr>
<tr>
<td></td>
<td>Speaker: Christopher Ritchlin</td>
</tr>
<tr>
<td>10.00 – 10.20</td>
<td>Coffee/Posters/Exhibits</td>
</tr>
<tr>
<td>10.30 – 12.00</td>
<td><strong>Plenary 2: Psoriatic disease epidemiology</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Jean–Hilaire Saurat, Philip Helliwell</td>
</tr>
<tr>
<td>10.30 – 10.50</td>
<td>Disease associations in psoriasis: indicators of systemic inflammation?</td>
</tr>
<tr>
<td></td>
<td>Speaker: Joel Gelfand</td>
</tr>
<tr>
<td>10.50 – 11.10</td>
<td>Psoriatic arthritis: Advances in phenotype and classification, what has changed since Moll and Wright?</td>
</tr>
<tr>
<td></td>
<td>Speaker: William Taylor</td>
</tr>
<tr>
<td>11.10 – 11.30</td>
<td>Psoriatic arthritis: Who has it, who gets it?</td>
</tr>
<tr>
<td></td>
<td>Speaker: Vinod Chandran</td>
</tr>
<tr>
<td>11.30 – 11.50</td>
<td>Pustular psoriasis: what is it, what makes the difference?</td>
</tr>
<tr>
<td></td>
<td>Speaker: Hervé Bachelez</td>
</tr>
</tbody>
</table>

### Complementary program

**Chairs:** Joachim Barth, Hoseah Waweru

Please note that the Complementary program’s sessions will be in hall C1-C3 located on level 2.

<table>
<thead>
<tr>
<th>Time</th>
<th><strong>Complementary program opens</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00</td>
<td>Welcome address by Lars Ettarp, President of IFPA</td>
</tr>
<tr>
<td>10.05 – 10.15</td>
<td>Introduction to the complementary program</td>
</tr>
<tr>
<td></td>
<td>Speaker: Joachim Barth</td>
</tr>
<tr>
<td>10.15 – 10.35</td>
<td>Psoriasis of the skin – present knowledge</td>
</tr>
<tr>
<td></td>
<td>Speaker: Peter van de Kerkhof</td>
</tr>
<tr>
<td>10.35 – 10.55</td>
<td>Psoriatic arthritis – present knowledge</td>
</tr>
<tr>
<td></td>
<td>Speaker: Philip Mease</td>
</tr>
<tr>
<td>10.55 – 11.15</td>
<td>Comorbidities – a new important aspect of psoriasis</td>
</tr>
<tr>
<td></td>
<td>Speaker: Mona Ståhle</td>
</tr>
</tbody>
</table>
# Scientific Program

<table>
<thead>
<tr>
<th>Time</th>
<th>GENERAL PROGRAM</th>
</tr>
</thead>
</table>
| 11.50 – 12.00 | ABSTRACT PRESENTATION. Advanced Cardiometabolic Phenotyping in Psoriasis: Links Between Psoriasis and Cardiovascular Disease?  
Presenter: Nehal Mehta |
| 12.00 – 13.30 | Lunch/Posters/Exhibits                                                          |
| 12.15 – 13.15 | INDUSTRY-SPONSORED LUNCH SEMINAR – Celgene – The dawn of change in psoriatic disease treatment |
| 13.30 – 15.30 | Plenary 3: Psoriatic disease around the world: ethnic, geographic and therapeutic considerations  
Chairs: Enno Christophers, Luis Espinosa |
| 13.30 – 14.00 | The psoriatic phenotypes: a global perspective  
Speaker: Christopher Griffiths |
| 14.00 – 14.20 | Psoriatic arthritis in Latin America: challenges in diagnosis and treatment  
Speaker: Sergio Toloza |
| 14.20 – 14.40 | Psoriasis in India: Clinical patterns and treatment challenges  
Speaker: Sunil Dogra |
| 14.40 – 15.00 | Psoriatic arthritis in South East Asia: disease characteristics and economic burden  
Speaker: Lai-Shan Tam |
| 15.00 – 15.20 | HIV and psoriasis: the African experience  
Speaker: Anisa Mosam |
| 15.20 – 15.30 | ABSTRACT PRESENTATION. Coronary risk estimation and other cardiovascular co-morbidities in moderate to severe psoriasis patients in Spain. RECOR study  
Presenter: Carmen Garcia-Calvo |
| 15.30 – 16.00 | Coffee/Posters/Exhibits                                                          |
| 16.00 – 16.30 | Key note lecture: Inflammatory mediators in cardiovascular disease with relevance to psoriatic disease  
Chairs: Peter van de Kerkhof, Oliver FitzGerald  
Speaker: James De Lemos |

## Complementary program

*Chairs: Joachim Barth, Hoseah Waweru*

Please note that the Complementary program’s sessions will be in hall C1-C3 located on level 2.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 11.15 – 11.35 | Factors provoking psoriasis and their prevention  
Speaker: Mark Lebwohl |
| 11.35 – 11.55 | Psychosocial burden of the disease  
Speaker: Sylvia van Beugen |
| 11.55 – 12.15 | Panel discussion                                                     |

The Blue Hall in the Stockholm City Hall.

*Photo: Moa Karlberg*

The Blue Hall in the Stockholm City Hall.

*Welcome reception at the Stockholm City Hall  
By invitation of the City of Stockholm and the Stockholm City Council*
## Friday June 29

### 07.15 – 08.15
**Interesting psoriasis & psoriatic arthritis clinical cases**  
*Chair: Alan Menter*  
*Three interesting cases from around the world with active audience participation*  
*Panel chair: Dafna Gladman*  
*Panelists/presenters: Vermén Verallo-Rowell, André Carvalho, Philip Mease*  

### 07.30 – 08.30
**Posters/Exhibits**

### 08.30 – 10.00
**Plenary 4: Psoriatic disease genetics**  
*Chairs: Alan Menter, Philip Mease*  
- **08.30 – 08.50**  
  **The genetics of psoriasis: old risks, novel loci**  
  *Speaker: Anne Bowcock*  
- **08.50 – 09.10**  
  **Are there genes that predispose psoriasis patients to psoriatic arthritis?**  
  *Speaker: Proton Rahman*  
- **09.10 – 09.25**  
  **Are skin and joints related?**  
  – Five key arguments pro  
  *Speaker: Dafna Gladman*  
- **09.25 – 09.40**  
  **– Five key arguments against**  
  *Speaker: Jonathan Barker*  
- **09.40 – 10.00**  
  **Panel discussion**  

### 10.00 – 10.30
**Coffee/Posters/Exhibits**

### 10.30 – 12.00
**Plenary 5: Screening tools and outcome measures to assess psoriatic disease**  
*Chairs: Amit Garg, William Taylor*  
- **10.30 – 10.50**  
  **Outcomes measures for psoriatic disease**  
  *Speaker: Alan Menter*  
- **10.50 – 11.10**  
  **Screening tools for psoriatic arthritis: The role of the dermatologist in early diagnosis**  
  *Speaker: Abrar Qureshi*  
- **11.10 – 11.30**  
  **Composite indices and integrated assessment across the psoriatic spectrum**  
  *Philip Helliwell*  
- **11.30 – 11.50**  
  **Imaging for the diagnosis of psoriatic arthritis: Which and when?**  
  *Dennis McGonagle*  
- **11.50 – 12.00**  
  **ABSTRACT PRESENTATION. High prevalence of articular involvement in patients with severe psoriasis with poor performance of screening questionnaire**  
  *Presenter: Muhammad Haroon*  

### Complementary program
*Chairs: Joachim Barth, Hoseah Waweru*

Please note that the Complementary program’s sessions will be in hall C1-C3 located on level 2.

<table>
<thead>
<tr>
<th>Time</th>
<th>Complementary program opens for the day</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00 – 10.20</td>
<td><strong>Local treatment – still basic treatment</strong></td>
</tr>
<tr>
<td></td>
<td><em>Speakers: Gail Todd &amp; Judy Wallace</em></td>
</tr>
<tr>
<td>10.20 – 10.40</td>
<td><strong>Treatment of “difficult to treat” areas</strong></td>
</tr>
<tr>
<td></td>
<td><em>Speaker: Birgitta Wilson Claréus</em></td>
</tr>
<tr>
<td>10.40 – 11.00</td>
<td><strong>Phototherapy – new aspects of an old method</strong></td>
</tr>
<tr>
<td></td>
<td><em>Speaker: Joachim Barth</em></td>
</tr>
<tr>
<td>11.00 – 11.20</td>
<td><strong>Conventional systemic treatment in psoriasis and psoriatic arthritis</strong></td>
</tr>
<tr>
<td></td>
<td><em>Speaker: Hoseah Waweru</em></td>
</tr>
</tbody>
</table>
### Scientific Program

<table>
<thead>
<tr>
<th>Time</th>
<th>GENERAL PROGRAM</th>
<th>Time</th>
<th>Complementary program</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.00 – 13.30</td>
<td>Lunch/Posters/Exhibits</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.15 – 13.15</td>
<td><strong>INDUSTRY-SPONSORED LUNCH SEMINAR – Janssen</strong> – Asking questions of biologic therapies: a joint approach</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 13.30 – 15.30 | **Plenary 6: Psoriatic disease through the life cycle**<br>
*Chairs: Edgardo Chouela, Neil McHugh* |            | **Complementary program**<br>**Chairs: Joachim Barth, Hoseah Waweru**<br>**Please note that the Complementary program’s sessions will be in hall C1-C3 located on level 2.** |
| 13.30 – 13.50 | Depression, anxiety and coping: Is the impairment from psoriasis cumulative over a patient’s lifetime?<br>
*Speaker: Alexa Kimball* | 11.20 – 11.40 | **Biologics – a breakthrough in psoriasis treatment?**<br>
*Speaker: Jonathan Barker* |
| 13.30 – 13.50 | Therapeutic challenges for females of child-bearing age<br>
*Speaker: Alan Menter* | 11.40 – 12.00 | **Panel discussion** |
| 14.10 – 14.30 | Psoriasis in childhood and adolescence: clinical characteristics and treatment perspectives<br>
*Speaker: Ricardo Romiti* | 15.10 – 16.00 | Coffee/Posters/Exhibits                                                              |
| 14.30 – 14.50 | Late onset psoriatic arthritis: is it different?<br>
*Speaker: Ignazio Olivieri* | 16.00 – 16.30 | **Key note lecture: Inflammatory bowel disease and psoriasis: common genetic and pathogenetic pathways?**<br>
*Chairs: Ricardo Romiti, Ignazio Olivieri*<br>
*Speaker: Yehuda Chowers* |
| 14.50 – 15.10 | What do we know about the natural history of psoriasis?<br>
*Speaker: Mona Ståhle* | 16.45 – 17.45 | **INDUSTRY-SPONSORED SATELLITE SYMPOSIUM – Abbott International** – Let’s talk psoriasis! Psoriasis as a multifaceted, systemic, inflammatory disease: Are patients and physicians talking the same language? |
| 15.10 – 15.20 | **ABSTRACT PRESENTATION.** Different genetic background separates prepubertal and postpubertal onset of psoriasis<br>
*Presenter: Josefin Lysell* | 18.00 – 18.45 | **INDUSTRY-SPONSORED SATELLITE SYMPOSIUM – Novartis** – IL-17A: Leading Pathway to Psoriasis and Therapeutic Innovation |
| 15.20 – 15.30 | **ABSTRACT PRESENTATION.** Prevalence of overweight/obesity in psoriasis population and its therapeutic consequences in clinical setting. Experience from Biobadaderm<br>
*Presenter: Jose-Manuel Carrascosa* | 19.30 | Conference dinner at the Vasa Museum |

Conference dinner at the restaurant in the Vasa Museum, where you can see the Royal Warship Vasa that came to such a dramatic end in Stockholm on August 10th 1628.
## Scientific Program

### Saturday June 30

<table>
<thead>
<tr>
<th>Time</th>
<th>GENERAL PROGRAM</th>
<th>Time</th>
<th>Complementary program</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.15 – 08.15</td>
<td><strong>INDUSTRY-SPONSORED BREAKFAST SEMINAR – Eli Lilly</strong> (Note: hall C1–C3) – IL-17 and Psoriasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>07.30 – 08.30</td>
<td>Posters/Exhibits</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.30 – 09.30</td>
<td><strong>Plenary 7: Psoriatic disease – pathogenic insights</strong></td>
<td>09.00 – 10.00</td>
<td><strong>Key note lecture: Comparative Effectiveness Analysis and Pharmacoeconomic modelling of biologics in Psoriasis</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Vermén Verallo-Rowell, Christopher Ritchlin</td>
<td></td>
<td>Chairs: Joachim Barth, Hoseah Waweru</td>
</tr>
<tr>
<td>08.30 – 08.50</td>
<td>The inflammasome and the alarmins: what starts psoriatic inflammation?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Jürgen Schauber</td>
<td>10.00 – 10.30</td>
<td>Complementary program opens for the day</td>
</tr>
<tr>
<td>08.50 – 09.10</td>
<td>Synovitis in psoriatic arthritis: what can immunohistochemistry tell us?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Arno van Kuijk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.10 – 09.30</td>
<td>What do T cells see in psoriasis lesions?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Jörg Prinz</td>
<td>10.00 – 10.20</td>
<td><strong>Psoriasis and psoriatic arthritis in childhood</strong></td>
</tr>
<tr>
<td>09.30 – 10.00</td>
<td><strong>Key note lecture: Comparative Effectiveness Analysis and Pharmacoeconomic modelling of biologics in Psoriasis</strong></td>
<td></td>
<td>Speaker: Josefin Lysell</td>
</tr>
<tr>
<td></td>
<td>Chairs: Vermén Verallo-Rowell, Christopher Ritchlin</td>
<td>10.20 – 11.00</td>
<td><strong>Impact of psoriasis on daily life activities</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: Aslam Anis</td>
<td></td>
<td>Speaker: Jörg Prinz</td>
</tr>
<tr>
<td>10.00 – 10.30</td>
<td>Coffee/Posters/Exhibits</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30 – 12.00</td>
<td><strong>Plenary 8: Systemic therapies in psoriatic disease</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Gail Todd, Arthur Kavanaugh</td>
<td>11.00 – 11.20</td>
<td><strong>Diet in psoriasis and psoriatic arthritis</strong></td>
</tr>
<tr>
<td>10.30 – 10.50</td>
<td>Methotrexate usage globally for psoriatic disease</td>
<td></td>
<td>Speaker: Anja Näslund</td>
</tr>
<tr>
<td></td>
<td>Speaker: Menno De Rie</td>
<td>11.20 – 11.40</td>
<td><strong>Dermatologic nursing in psoriasis</strong></td>
</tr>
<tr>
<td>10.50 – 11.10</td>
<td>Do traditional DMARDs work in psoriatic arthritis?</td>
<td></td>
<td>Speaker: Barbara Page</td>
</tr>
<tr>
<td></td>
<td>Speaker: Neil McHugh</td>
<td>11.40 – 12.00</td>
<td><strong>Panel discussion</strong></td>
</tr>
<tr>
<td>11.10 – 11.30</td>
<td>TNF antagonists in psoriatic arthritis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Philip Mease</td>
<td>12.00 – 12.10</td>
<td><strong>Closing remarks</strong></td>
</tr>
<tr>
<td>11.30 – 11.50</td>
<td>TNFα antagonists and p40 antibodies in psoriasis: similarities and differences</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Caitriona Ryan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.50 – 12.00</td>
<td><strong>ABSTRACT PRESENTATION.</strong> Secukinumab, a fully human anti-interleukin-17A antibody, improves signs and symptoms of psoriatic arthritis: A 24-week, double-blind, placebo-controlled, multicenter trial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Presenter: I McInnes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please note that the Complementary program’s sessions will be in hall C1-C3 located on level 2.
Scientific Program

<table>
<thead>
<tr>
<th>Time</th>
<th>GENERAL PROGRAM</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.00 – 13.30</td>
<td>Lunch/Posters/Exhibits</td>
</tr>
<tr>
<td>12.15 – 13.15</td>
<td>INDUSTRY-SPONSORED LUNCH SEMINAR – LEO Pharma – Beyond the symptoms: Understanding and overcoming the real impact of psoriasis on patients</td>
</tr>
</tbody>
</table>
| 13.30 – 15.00 | Plenary 9: Psoriasis and psoriatic arthritis: disease activity and therapeutic challenges  
  Chairs: Mark Lebwohl, Ennio Lubrano |
| 13.30 – 13.50 | Evaluation and treatment of psoriatic nail disease  
  Speaker: Phoebe Rich |
| 13.50 – 14.10 | Minimal disease activity in psoriatic arthritis: indicator of remission or potential progression?  
  Speaker: Kurt de Vlam |
| 14.10 – 14.30 | Treatment algorithms and quality guidelines  
  Speaker: Arthur Kavanaugh |
| 14.30 – 14.50 | Body weight and treatment response  
  Speaker: Lluis Puig Sanz |
| 14.50 – 15.00 | ABSTRACT PRESENTATION. Predictive biomarkers for high responsiveness to treatment, and biomarkers associated with clinical response to treatment, in psoriasis patients treated with the anti-IL-17A monoclonal antibody, ixekizumab  
  Presenter: Robert Hoffman |
| 15.00 – 15.30 | Coffee/Posters/Exhibits                                                          |
| 15.30 – 16.50 | Plenary 10: Concluding lectures  
  Chairs: Mona Ståhle, Björn Güdþjörnsson |
| 15.30 – 15.50 | Psoriatic disease care: a team approach  
  Speaker: Alice B. Gottlieb |
| 15.50 – 16.10 | Systemic therapy: does it affect cardiovascular risk?  
  Speaker: Wolf-Henning Boehncke |
| 16.10 – 16.30 | Psoriasis and the burden of disease: calling for worldwide action  
  Speaker: Gerald G. Krueger |
| 16.30 – 16.50 | IFPA’s work for worldwide recognition of psoriasis as a serious noncommunicable disease  
  Speaker: Lars Ettarp |

Closing of scientific program

Sunday July 1

IFPA Member meeting (closed session)  
World Psoriasis Day Supporters Training Meeting  
(pre-registration only)
Go beyond the surface at Booth 6

For a deeper look at results on and below the skin with HUMIRA™


Indications: psoriasis, psoriatic arthritis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, crohn’s disease. HUMIRA is presented as solution for injection, pre-filled syringe/pen, 40 mg. For complete information regarding indications, contraindications, warnings and precautions, adverse reactions, price and dosing, see: www.fass.se

Abbott Scandinavia AB, Box 1498, 171 29 Solna, Sweden.
Telephone +46 8 546 567 00. www.abbott.se

Please see Booth Representative for Indications, Important Treatment Considerations, and SPC.


©2012 Abbott Laboratories  Abbott Park, IL 60064  Al 822303  March 2012
Social Program

All social events are available for delegates and accompanying persons if pre-booked in the registration form. For late bookings please contact the registration desk to inquire about availability.

Wednesday, 27 June at 18.00

Conference Reception
The conference reception will take place at the conference venue on level 5, where light refreshments will be served.

Location: Waterfront Congress Centre, level 5
Time: 18.00 – 19.00

Welcome Program
The welcome program features a short welcome from the President of the conference, Dr Alan Menter, and from the President of IFPA, Lars Ettarp, followed by an introduction to IFPA by Kathleen Gallant, Secretary of IFPA and a special viewing of IFPA’s international documentary film project.

Location: Waterfront Congress Centre, level 5, room A3/A4
Time: 19:00 – 20:00

Please note: Delegates and accompanying persons must be pre-registered for the above events.

Thursday, 28 June at 19.00

Reception hosted by the City of Stockholm and the County of Stockholm
The reception takes place at the City Hall of Stockholm, one of the best known buildings in Sweden. It holds the most exclusive ballroom in Stockholm, hosting the yearly Nobel Banquet. The City Hall is famous for its hospitality, its unique art treasures, magnificent banquetttes and intriguing history - attracting close to 400,000 visitors each year. Light refreshments will be served.

Location: Stockholm City Hall
Time: 19.00 (sharp)

Please note: Delegates and accompanying persons must be pre-registered. The official invitation card from the City of Stockholm should be shown at the entrance. The ticket received together with the name badge should be exchanged for the official card (see ticket for further details).

Friday, 29 June at 19.30

Conference Dinner
Welcome to a truly unique conference dinner in the spectacular Vasa museum with the magnificent warship Vasa as your dining companion. The Vasa sank on her first voyage in 1628, and has since her salvage in 1961 been one of the most beloved and awe-inspiring sights in Stockholm. The dinner, featuring local delicacies, will be followed by dance to live music in the Vasa Museum restaurant, which has a beautiful view over the Stockholm harbour inlet. There the bar will also be open to serve the guests refreshing beverages (not included in the dinner price).

Location: The Vasa Museum, Galärvarvsvägen 14, Djurgården, Stockholm
Time: 19.30 (sharp) – 00.30
Price: SEK 700 (excl. VAT)

Please note: Please bring your ticket received upon registration. The temperature in the banquet hall is kept at a steady 18° C for preservation purposes, so make sure to dress accordingly. You can read more about the museum at www.vasamuseet.se/en/.

How to get here:
WALK: From the Central Station. Approximate time: 30 minutes.
From Karlaplan station. Approximate time: 10 minutes.
TRAM: The easiest way to get to the Vasa Museum is by tram. From the city centre (by Sergels torg square, on Hamngatan street) take tram number 7 towards Waldemarsudd.
BUS: Bus 44 to bus stop Nordiska museet/Vasamuseet.
Bus 69 and 76 to bus stop Djurgårdsbron.
METRO: Red line to station Karlaplan. From there a 10 minute walk or bus 44 to bus stop Nordiska museet/Vasamuseet.
FERRY: Ferry from Slussen all year round and from Nybroplan during the summer.

Visit www.si.se for timetables and other information about the tram, the buses and the metro.
Novartis proudly supports the 3rd World Psoriasis & Psoriatic Arthritis Conference in its efforts to assist patients and their families.

Please visit the Novartis Exhibit #9 at www.novartis.com

Lilly salutes the International Federation of Psoriasis Associations.
Hotels and social event locations

The easiest way to get to the Vasa Museum is by tram. From the city centre (by Sergels torg square, on Hamngatan street) take tram number 7 towards Waldemarsudde.

Please Join Us for an Educational Symposium entitled,

**IL-17A: Leading Pathway to Psoriasis and Therapeutic Innovation**

**CHAIRMAN**
Carle Paul, MD, PhD
Department of Dermatology, Paul Sabatier University and Toulouse University Hospital, Toulouse, France

**AGENDA**
> New insights on the pathophysiology of psoriasis  
> New biologic agents targeting the IL-17 pathway

Friday, 29 June 2012  |  18:00-18:45
Stockholm Waterfront Congress Centre  
Nils Ericsson Plan 4  
A1 Plenary Hall
The dawn of change in psoriatic disease treatment

Discover how patients and doctors can partner to improve care in psoriatic disease

Thursday, 28 June 2012, 12:15–13:15
Main Auditorium, Stockholm Waterfront Congress Centre

Peter van de Kerkhof
Radboud University
Nijmegen, The Netherlands

Ottfrid Hillmann
President
EUROPSO

Carle Paul
Paul Sabatier University
Toulouse, France

Kim Papp
Probity Medical Research
Waterloo, ON, Canada

With inputs from patients and clinical experts, this forum will explore ways to build partnerships for a common commitment to psoriatic disease treatment.

Seminar arranged and sponsored by Celgene International

LEO Pharma invites you to
LEO Symposium Saturday, 30th June,
12:15 - 13:15

Beyond the symptoms:
Understanding and overcoming the real impact of psoriasis on patients.

Visit the LEO booth #1 for more information

Look forward to seeing you!

Helping people living with psoriasis.
3rd World Psoriasis & Psoriatic Arthritis Conference 2012 – Final program

Stockholm Waterfront Congress Centre

Exhibition

1. LEO Pharma
2. Pfizer
3. Pfizer
4. Coffee area
5. IFPA
6. Abbott
7. Janssen
8. Janssen
9. Novartis
10. Novartis
11. Lüllau Engineering
12. GlobalMed Technologies
13. Kernel Medical Equipment
14. Celgene
15. Celgene
16. Satellite Symposia information
17. Upcoming events
18. H. Waldmann
19. Quantel Derma
20. Spa Smrdáky
21. Information booth
22. The Swedish Psoriasis Association
23. ISNG
24. IPC
25. BADV
26. PsoAfrica
27. PsorAsia
28. LATINAPSO
29. EUROPSO

Central booth – IFPA Under the Spotlight

A1 – Auditorium
C1 – C3 Complementary program
21 – Press room
22 – Staff room
23 – IFPA Meeting room
24 – IFPA Meeting room
37 – Speakers’ preview room
Balcony – Poster exhibition
Reducing the Burden of Psoriasis and Psoriatic Arthritis: A Framework for Action

Faculty

Professor Mona Stähle
Karolinska University Hospital
Karolinska Institute
Stockholm, Sweden

Professor Jonathan Barker
St John’s Institute of Dermatology (King’s College London)
London, England

Dr Philip Mease
Swedish Medical Center
University of Washington School of Medicine
Seattle Rheumatology Associates
Seattle, Washington USA
General information

Abstract book
Accepted abstracts are published in the conference abstract book, which is distributed to all delegates in the conference bag.

Badges
The participant name badge will be provided at the registration desk. All participants are requested to wear the badge throughout the conference. Only badge holders will be admitted to the sessions.

Business centre
A business centre is available within the venue located on level 3 and will be open during the conference hours.

Certificate of attendance
You will find a certificate of attendance in the conference bag.

CME Credits
A Certificate of attendance will be available for all participants attending the conference. For full participation 18 EACCME credit hours will be awarded.

EACCME credits are recognized by the American Medical Association (AMA) towards the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, please contact the AMA.

In order to collect your CME certificate, please complete the survey included in the conference bag. Return the completed survey to the registration desk, with start from Friday 29 June at 14.00, in return for the CME certificate.

Cloakroom
The cloakroom is located on the same level as the main entrance (level 4). The cloakroom is open during the conference hours. The cost for using the cloakroom is SEK 20 per item and cash or credit card payment is possible.

Conference organizer
All matters regarding registration, hotel booking, social events, abstract handling, exhibition management and general information are managed by Congrex Sweden AB. Congrex Sweden AB has been appointed official conference organizer for this event. The Congrex Group works internationally with offices in Sweden, The Netherlands, United Kingdom and Latin America, offering integrated solutions for the association services industry and corporate and governmental meetings. For more information, please visit: www.congrex.com

Disclaimer/Liability
The conference organizers cannot accept liability for injuries or losses of whatever nature incurred by participants and/or accompanying persons, nor for loss of or damage to their luggage and/or personal belongings. Please check the validity of your own travel insurance. All reasonable endeavours will be made to hold the 3rd World Psoriasis & Psoriatic Arthritis Conference 2012 and to present its program as scheduled under circumstances which assure the comfort and safety of all participants and accompanying persons. However, neither the IFPA nor its committees, representatives or agents, shall be held liable by any person as a result of the cancellation of the conference or of any of the arrangements, programs or plans connected therewith, or for any injury, damage or inconvenience which may be suffered by any person while travelling to or from, or during such person’s presence in Sweden in connection with this conference. Participants and accompanying persons are advised to purchase their own insurance against any such occurrences.

Emergency phone numbers
Police 112
Ambulance 112
Fire brigade 112

Exhibition
See page 17 for further details.

Evaluation
After the conference you will receive an evaluation form by e-mail.
Your opinion is very important for us and we appreciate that you take your time to fill it out.

Hearing aid
A limited number of receivers for hearing aid are available in the main hall only – A1.
Please contact the hall hostess for assistance with the receiver.

Internet
Wireless internet will be available within the conference venue.
The password is psoriasis.

Language
The official conference language is English. No simultaneous interpretation will be made.

Lost and found
Contact the registration desk in case of personal belongings being lost or found. Belongings not picked up during the conference will be handed over to Waterfront.

Meals
Morning and afternoon coffee will be served in the exhibition area and on level 2. Lunches are not included in the registration fee. However, there are several restaurants in the vicinity of the conference venue.

Smoking policy
This is a non-smoking conference. Sweden has a non-smoking policy, i.e. smoking is prohibited in public buildings, public transport, taxis, buses and trains.

Speakers’ preview room
Speakers are requested to use the facility to ensure that their presentation projects clearly and in the correct order. Presentations that haven’t been admitted previously, should be handed over to the technical staff a minimum of 2 hours before the session starts. Presentations received after this deadline cannot be guaranteed optimal audio-visual support. The speakers’ preview room will be in Room 37.

PUT PSORIASIS ON THE AGENDA NOW!
JOIN IFPA’S CAMPAIGN BY HAVING YOUR PICTURE TAKEN IN THE IFPA BOOTH AND GET A FREE WORLD PSORIASIS DAY PIN.
STELARA® 45 mg solution for injection in pre-filled syringe

**INDICATIONS:** Treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA. **ADMINISTRATION:** Under the guidance and supervision of a physician experienced in diagnosis and treatment of psoriasis. Subcutaneous injection. Avoid areas with psoriasis. For self-injecting patients ensure appropriate training, follow-up and monitoring during treatment. Adults & Elderly-Patients ≥ 100 kg, 90 mg at week 0 followed by a 90 mg dose at week 4, then every 12 weeks. Patients >100 kg, 90 mg at week 0 followed by a 90 mg dose at week 4, then every 12 weeks (45 mg was less effective in these patients). Consider discontinuation if no response after 28 weeks. Not recommended. Patients >100 kg, 90 mg at week 0 followed by a 90 mg dose at week 4, then every 12 weeks. Patients >100 kg, 90 mg at week 0 followed by a 90 mg dose at week 4, then every 12 weeks (45 mg was less effective in these patients). Consider discontinuation if no response after 28 weeks. Not recommended. **CONTRAINDICATIONS:** Hypersensitivity to product; clinically important, active infection. **PRECAUTIONS:** Infections: Potential to increase risk of infections and reactivate latent infections. Caution in patients with a chronic infection or history of recurrent infection, particularly TB. Patients should be evaluated for tuberculosis prior to initiation of STELARA. Consider anti-tuberculosis therapy prior to initiation of STELARA in patients with past history of latent or active tuberculosis. Patients should seek medical advice if signs or symptoms suggestive of an infection occur. If a serious infection develops, they should be closely monitored and STELARA should not be administered until infection resolves. **SIDE EFFECTS:** Hypersensitivity reactions (rash, urticaria), cellulitis, viral upper respiratory tract infection, depression, dizziness, headache, pharyngolaryngeal pain, nasal congestion, diarrhea, pruritus, back pain, myalgia, arthralgia, fatigue, injection site erythema, antibodies to ustekinumab. **INTERACTIONS:** Stelara® is indicated for the treatment of moderate-to-severe plaque psoriasis1.

Be inspired and see how together we can make a difference to psoriasis patients - visit the Stelara® stand at WPPAC 2012.

Stelara® is indicated for the treatment of moderate-to-severe plaque psoriasis1.
Stockholm and Sweden

Arlanda Airport
Arlanda Airport is located 49 km North of Stockholm. The Arlanda Express is the train service that links Stockholm City with the Airport. The journey normally takes 20 minutes from the Central Station.

Taxi: We recommend that you request a fixed price from the city to the airport, approx. SEK 550.

Bus: There is a direct bus connection from the City Terminal/Central station to Arlanda Airport. The journey takes about 40 minutes and costs SEK 100. The bus leaves every 10 minutes.

Business hours & shopping
Shops are open between 10.00 and 18.00 hrs on weekdays and from 10.00 to 15.00 on Saturdays. Shops in the city centre have extended opening hours, some even on Sundays between 12.00 and 16.00 hrs.

Climate and clothing
The average temperature in June is around 18 C (64 F).

Credit cards
International credit cards are accepted for payments in hotels, restaurants and shops.

Currency
The currency in Sweden is the Swedish krona, SEK.

Time zone
Sweden is in the Central European Time zone.

Tourist information
A representative from the Stockholm Visitors Board will be present in the information desk from 12.00 to 17.00 during the conference where you will be able to book sightseeing tours, purchase Stockholm cards and transportation cards. For more extensive tourist information about Stockholm please visit the website: www.visitstockholm.com/en/. You will find more practical information and tips about Sweden on www.visitsweden.com.

Transportation
The city centre of Stockholm is easily accessible by foot, and the transportation network with buses, trams and underground is extensive. For more information about public transportation, visit www.sl.se. If you instead choose to travel by taxi, make sure that it is an approved taxi with metered fare. These taxis always have yellow license plates. Credit cards are readily accepted and often preferred to cash.
Abstract Titles

Psoriasis and Psoriatic Arthritis relationship

P002 Early treatment of psoriatic arthritis is associated with improved outcomes: findings from the etanercept PRESTA trial
Kirkham, Bruce1; Li, Wenzhi2; Boggs, Robert1; Nab, Henk1; Tarallo, Miriam1
1Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom; 2Pfizer Inc., Collegeville, PA, United States; 3Pfizer Europe, Rome, Italy

P003 Bone alterations in psoriatic patients – an early sign of psoriatic arthritis?
Finzel, Stephanie1; Benner, Regina1; Engbrecht, Matthias1; Schett, Georg1; Rech, Jürgen1; Sticherling, Michael1
1Department of Internal Medicine 3, Rheumatology and Immunology, University Hospitals Erlangen, Erlangen, Germany; 2Department of Dermatology, University Hospitals Erlangen, Erlangen, Germany

P004 Effects of PUVA and narrowband UVB on adenosine deaminase activities in plasma and tissue samples of patients with psoriasis
Ozsurt, Kemal1; Ozturk, Perihan1; Yıldız, Sinem1; Uksal, Umit1
1KSU Medicine Faculty, Dermatology, Kahramanmaraş, Turkey; 2Kayseri State Hospital, Dermatology, Kayseri, Turkey; 3Taksim Alman Hospital, Dermatology, Istanbul, Turkey

P005 Unilateral psoriasis: a case report
Yavuz, Cihat1; Ataseven, Arzu1; Ozturk, Perihan1
1Department of Dermatology, Konya Education and Research Hospital, Konya, TURKEY, Konya, Turkey; 2Department of Dermatology, Kahramanmaraş Sütçü İmam University, Kahramanmaraş, TURKEY, Kahramanmaraş, Turkey

P006 Two cases of concomitant vitiligo and psoriasis
Ataseven, Arzu1; Ozturk, Perihan1; Karaosmanoglu, Ilknur1
1Department of Dermatology, Konya Education and Research Hospital, Konya, TURKEY, Konya, Turkey; 2Department of Dermatology, Kahramanmaraş Sütçü İmam University, Kahramanmaraş, TURKEY, Kahramanmaraş, Turkey; 3Department of Pathology, Konya Education and Research Hospital, Konya, TURKEY, Konya, Turkey

P007 The prevalence of rheumatologist-diagnosed psoriatic arthritis in psoriasis patients in European/North American dermatology clinics: Results of the PREPARE study
Mose, Philip1; Papp, Kim A1; Gladman, Dafna1; Thaci, Diamant1; Northington, Robert1; Fisman, Joanne1; Boggs, Robert1; Alvarez, Daniel1
1Swedish Medical Center, University of Washington School of Medicine, Seattle, WA, United States; 2Probit Medical Research, Waterloo, Ontario, Canada; 3University of Toronto, Toronto, Ontario, Canada; 4J. W. Goethe University, Frankfurt, Germany; 5Pfizer Inc, Collegeville, PA, United States

P008 Epidemiology of psoriasis and psoriatic arthritis in Scotland
McHattie, Lorna W1; Diack, H. Lesley1; Stewart, Derek1; Ormerod, Anthony O1; Burden, A. David1
1Robert Gordon University, School of Pharmacy and Life Sciences, Aberdeen, United Kingdom; 2University of Aberdeen, Aberdeen, United Kingdom; 3Greater Glasgow and Clyde Health Board, Department of Dermatology, Glasgow, United Kingdom

P009 Comparison of composite disease activity scores in psoriatic arthritis
Hellwell, Philip1; FitzGerald, Oliver1; Pedersen, Ronald1; Bananis, Eustratios1
1Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom; 2St. Vincent’s University Hospital Dublin, Dublin, Ireland; 3Pfizer Inc., Collegeville, PA, United States

P010 High prevalence of articular involvement in patients with severe psoriasis with poor performance of screening questionnaires
Haroon, Muhammad1; Kirby, Brian1; FitzGerald, Oliver1
1St Vincent’s University Hospital, Department of Rheumatology, Dublin, Ireland; 2St Vincent’s University Hospital, Department of Dermatology, Dublin, Ireland

P011 Prevalence of psoriatic arthritis in psoriatic patients attending dermatologists’ units in Spain. PREVAl study
Zarco, Pedro1; López-Estebanar, Jose Luis1; Fernández-Sueiro, Jose Luis1; García-Caño, Carmen1
1Fundación Hospital Alcorcón, Department of Rheumatology, Alcorcón, Madrid, Spain; 2Fundación Hospital Alcorcón, Department of Dermatology, Alcorcón, Madrid, Spain; 3Hospital Universitario Juan Canalejo, Department of Rheumatology, A Coruña, Spain; 4Pfizer Spain, Medical Department, Madrid, Spain

Genetics

P012 Search and exploration candidate genes and their role in pathogenesis of psoriasis
Sobolev, Vladimir; Soboleva, Anna; Mezentsev, Alexandre; Bruskin, Sergey
Institute of General Genetics, Functional Genomics, Moscow, Russian Federation

P013 Risk variants for psoriasis in a large case-control collection and association with clinical subphenotypes
Julia, Antonio1; Tortosa, Raúl1; Hernanz, José Manuel1; Calete, Juan D1; Fonseca, Eduardo1; Ferrándiz, Carlos1; Unamuno, Pablo1; Puig, Luis1; Fernández-Sueiro, José Luis1; Sanmarti, Raimon1; Rodríguez, Jesús1; Gratacos, Jordi1; Dauden, Esteban1; Sánchez-Carazo, José Luis1; López-Estebanar, José Luis1; Moreno-Ramirez, David1; Queiroz, Gabriel1; Montilla, Carlos1; Torre-Alonso, Juan Carlos1; Pérez-Vegueta, José Javier1; Vanaclocha, Francisco1; Herrera, Enrique1; Muñoz, Fernández, Santiago1; González, Carlos1; Roig, Daniel1; Erra, Alba1; Acosta, Isabel1; Fernández-Nebro, Antonio1; Zarco, Pedro1; Alonso, Arnald1; López-Lasanta, María1; García-Montero, Andrés1; Gelpí, Josep Luis1; Absher, Devin1; Marsal, Sara1
1Val d’Hebron Hospital Research Institute, Barcelona, Spain; 2Hospital Universitario Gregorio Marañón, Madrid, Spain, 3Hospital Clinic de Barcelona, Spain; 4Complejo Hospitalario Juan Canalejo, A Coruña, Spain; 5Hospital Universitario Germans Trias i Pujol, Barcelona, Spain; 6Hospital Universitario de Bellvitge, Barcelona, Spain; 7Hospital Parc Taulí, Sabadell, Spain; 8Hospital Universitario La Princesa, Madrid, Spain; 9Hospital General Universitario de Valencia, Valencia, Spain; 10Hospital Universitario Fundación Alcorcón, Madrid, Spain; 11Hospital Universitario Virgen Macarena, Sevilla, Spain; 12Hospital Universitario Central de Asturias, Oviedo, Spain; 13Hospital Virgen de la Vega, Salamanca, Spain; 14Hospital Monte Naranco, Oviedo, Spain; 15Hospital de Jerez de la Frontera, Cádiz, Spain; 16Hospital Universitario 12 de Octubre, Madrid, Spain; 17Hospital Universitario Virgen de la Victoria, Málaga, Spain; 18Hospital Universitario Infanta Sofia, Madrid, Spain; 19Centre d’Atención Especializada de Cornellà, Barcelona, Spain; 20Hospital Sant Rafael, Barcelona, Spain; 21Hospital Regional Universitario Carlos Haya, Málaga, Spain; 22Universidad de Salamanca, Salamanca, Spain; 23Barcelona Supercom-
**Pathophysiology and immunobiology**

**P019** Anti-inflammatory potential of bacterial components

Zakostelska, Zuzana1; Kverka, Miloslav1; Klimesova, Klara1; Rossmann, Pavel1; van der Zee, Ruurd2; van Eden, Willem1; Tlaskalova-Hogenova, Helena1

1Institute of Microbiology AS CR, Department of Immunology and Gnotobiology, Prague, Czech Republic; 2University of Veterinary Medicine, Department of Infectious diseases and Immunology, Utrecht, Netherlands

**P020** The role of human microRNA-31 in psoriasis

Xu, Ning1; Meisgen, Florian1; Stähle, Mona1; Sonkoly, Enikő1; Pivarcsi, Andor1

1Karolinska Institutet, Unit of Dermatology, Department of Medicine, Stockholm, Sweden

**P021** Langerhans cells in psoriasis

Wkén, Maria1; Cheuk, Stanley1; Bergh, Kerstin1; Stähle, Mona1; Eidsmo, Liv1

Karolinska Institutet, Medicine, Stockholm, Sweden

**P022** Obesity and psoriasis - Vaspin as a possible link?

Röss, Katharina1; Saubach, Anja1; Tremel, Jenny1; Anderegg, Ulf1; Averbeck, Marco1; Bodenfors, Mare1; Ziemer, Mojana1; Beck-Sicking, Annette G2; Bluher, Matthias3; Simon, Jan C3

1University of Leipzig, Department of Dermatology, Venerology and Allergology, Leipzig, Germany; 2University of Leipzig, Institute of Biochemistry, Faculty of Life Sciences, Pharmacy; 3LIFE –Leipzig Research Center for Civilization Diseases, Leipzig, Germany; 4University of Leipzig, Department of Medicine, Medical Faculty; 5LIFE –Leipzig Research Center for Civilization Diseases, Leipzig, Germany

**P023** Anti-TNF-α therapy alters serum miRNA expression profiles in psoriasis patients

Pivarcsi, Andor1; Meisgen, Florian1; Xu, Ning1; Stähle, Mona1; Sonkoly, Enikő1

Karolinska Institutet, Dept of Medicine, Dermatology and Venerology Unit, Stockholm, Sweden

**P024** Skin equivalent as an experimental model to study psoriasis

Soboleva, Anna1; Mezentsev, Alexandre1; Sobolev, Vladimir1; Bruakin, Sergey1

Vavilov Institute of General Genetics, Functional Genomics, Moscow, Russian Federation

**P025** Small intestine microflora at psoriasis. Its possible role in pathogenesis.

Peslyak, Mikhail1; Gumayunova, Natalia1; Nesterov, Alex3; Potaturkina-Nesterova, Natalia1

1Kudits, Moscow, Russian Federation; 2Ulyanovsk State University, Ulyanovsk, Russian Federation

**P026** Differential scanning calorimetry analysis of human plasma in different psoriasis stages

Moezzi, Mehrdad1; Fekcès, Tamás1; Zapf, István1; Ference, Andrea1; Lorinczy, Dénes1

1Medical University of Pécs, Dermatology, Pécs, Hungary; 2University of Pécs, Medical School, Dermatology, Pécs, Hungary; 3University of Pécs, Medical School, Surgery, Pécs, Hungary; 4Semmelweis University, Medical School, Surgery, Budapest, Hungary; 5University of Pécs, Medical School, Biophysics, Pécs, Hungary

**P027** The role of miR-146a in innate immunity of keratinocytes

Meisgen, Florian1; Xu, Ning1; Stähle, Mona1; Sonkoly, Enikő1; Pivarcsi, Andor1

Karolinska Institutet, Dept of Medicine Solna, Stockholm, Sweden

**P028** FC gamma receptors in active psoriatic arthritis

Matt, Johann Peter1; Lindqvist, Ulla Ruth Kristina1; Kleinraud, Sandra1

1Department of medical sciences, Rheumatology, Uppsala university, Uppsala, Sweden; 2Dept. of Cell and Molecular Biology, Biomedical Center, Uppsala University, Uppsala, Sweden

**P029** Evaluation of cardio-protective role of methotrexate in psoriasis

Malhotra, Suresh1; Dhaliwal, Gurinder1; Puri, Karanjit1; Mahajan, Mridula2

1Govt medical collage, Dermatology, Amritsar, India; 2Govt medical collage, Biochemistry, Amritsar, India
The Journal of Rheumatology

First Release Articles
Current Issue
Archives
Authors/Reviewers

What you get
• Current
• Clinical
• Definitive

Where you get it
THE JOURNAL

To subscribe: visit jrheum.org online or send in your completed coupon below

Rates for 2012 calendar year
USA/INTERNATIONAL

INDIVIDUALS: Print + Online Online Only
- Individuals $310 US $260 US
- Multirate* $920 US
- Multirate (IP ranges) $495 US
- Basic (up to 4 users) $175 US
- Trainees** $136 US
- Annual (A&D) $80 US

*No change in my access requirements.
**Please renew at current rate
For terms of access visit jrheum.org
*Supervisor certification required below.

NAME OF SUPERVISOR: ________________________________
SUPERVISOR SIGNATURE: ________________________________
SUPERVISOR TELEPHONE: ________________________________

Mail completed form to: The Journal of Rheumatology
365 Brook Street East, Suite 901
Toronto, Ontario Canada M4V 3L4
or 1051 Clinton Street
Buffalo, NY, 14206-2863 USA

Please enter my 2012 subscription to The Journal of Rheumatology

Name (please print) ________________________________
Address ________________________________
City __________________ State/Province __________________
Country __________________ Zip/Postal Code __________________

Contact E-mail __________________
Amount Enclosed $ ________
Bill Me ________

Telephone Number __________________ Fax Number __________________

VISA/MasterCard Number __________________ Expiration Date __________________

Signature __________________

CVV __________________

All subscriptions are for the calendar year. Renewals for print subscriptions received after May 31, 2012 will be charged an additional $5 per issue. Back issues: 3 years including current year are available if in stock. Single copies are available at $30 each. Claims: US 2 months, elsewhere 4 months from issue date, e.g., March 1 and May 1, respectively, for the January issue. PRIVACY POLICY: For details of our privacy policy, visit our website at www.jrheum.org.
Abstract Titles continued

P030 Immune regulation at the border of psoriatic lesions
Ketiers, Ron; van Erp, Piet; de Boer-van Huizen, Roelie; Joosten, Irma; Koenen, Hans; van de Kerkhof, Peter
1Radboud University Nijmegen Medical Centre, Department of Dermatology, Nijmegen, Netherlands; 2Radboud University Nijmegen Medical Centre, Laboratory of Medical Immunology, Nijmegen, Netherlands

P031 Comparison between involved and uninvolved psoriatic skin in a pathological skin model produced with the self-assembly approach
Jean, Jessica; Duque-Fernandez, Alexandra; Bernard, Geneviève; Sancy, Jacques; Pouliot, Roxane
1Faculté de Pharmacie, Université Laval, Québec, Canada, Centre LOEX de l’Université Laval, Génie tissulaire et régénération, Québec, Canada; 2Département de Dermatologie, Hôpital de l’Enfant-Jésus, Québec, Canada

P032 Clinical and immunological response to treatment of psoriasis in the blue lagoon compared with narrow-band UVB monotherapy
Systemusdottir, HJ; Olafsson, JHF; Davidson, S; Brynjolfsdottir, A; Sigurgeirsson, B; Ludviksson, BR
1Salgrenska University Hospital, Department of Dermatology and Venerology, Gothenburg, Sweden; 2University Hospital of Iceland, Department of Dermatology and Venerology, Reykjavik, Iceland; 3University of Iceland, Faculty of Medicine, Reykjavik, Iceland; 4Blue Lagoon inc, Grindavik, Iceland; 5University Hospital of Iceland, Department of Immunology, Reykjavik, Iceland

P033 Systemically elevated Th1-, Th2- and Th17-associated chemokines in psoriasis
Ekman, Anna-Karin; Sigurdardottir, Gunnthorunn; Carlström, Maria; Karlul, Natalja; Jenmalm, Maria; Enerbäck, Charlotta
1Department of Clinical and Experimental medicine, Division of Cell biology and Dermatology, Linköping University, Linköping, Sweden; 2Department of Clinical and Experimental medicine, Division of Clinical immunology, Linköping University, Linköping, Sweden

P034 Characterization of skin resident T cells in psoriasis treated with UVB or anti-TNFalpha therapy
Cheuk Stanley, Wikén, Maria; Ståhle, Mona; Eidsmo, Liv
Karolinska Institutet, Department of Medicine Solna, Stockholm, Sweden

Epidemiology

P035 Psoriasis and psoriatic arthritis among natives and mestizos from the Andean mountains region of Peru
Toloza, Sergio; Vega-Hinojosa, Oscar; Chandran, Vinod; Valle-Oñate, Rafael; Espinoza, Luis R
1Hospital San Juan Bautista, Medicine, Catamarca, Argentina; 2Hospital III, Medicine, Juliaca, Peru; 3University of Toronto, Medicine, Toronto, Canada; 4Universidad de La Sabana, Medicine, Bogotá, Colombia; 5Louisiana State University, New Orleans, United States

P036 The Swedish Early Psoriatic Arthritis (SwePSA) registry. 5-year follow-up: worse outcomes for women compared to men.
Theander, Elle; Husmark, Tomas; Alenius, Gerd-Marie; Larsson, Per; Telemark, Anna; Geijer, Mats; Lindquist, Ulla R C
1Skåne University Hospital, Rheumatology, Malmö, Sweden; 2Falu Hospital, Rheumatology, Falun, Sweden; 3Umeå University Hospital, Public Health and Clinical Medicine, Umeå, Sweden; 4Karolinska University Hospital, Rheumatology, Stockholm, Sweden; 5Spenshult Rheumatological Hospital, Rheumatology, Oskarström, Sweden; 6Skånes University Hospital, Radiology, Lund, Sweden; 7Uppsala University Hospital, Medical Sciences, Rheumatology, Uppsala, Sweden

P037 Latent tuberculosis infection or tuberculin hyperergy? A three-year retrospective study on patients with psoriasis in an endemic area
Solovyan, Cătălin; Chiticariu, Elena; Stoia Dejka, Irina
1University of Medicine and Pharmacy “Victor Babes”, Dermatology Department, Timisoara, Romania; 2County Hospital, Dermatology Clinic, Timisoara, Romania; 3Victor Babes Hospital, Pulmonology Clinic, Timisoara, Romania

P038 PSOLAR: Global update of a multicentre, open registry of psoriasis patients
Pepp, Kim; Strober, Bruce; Ho, V; Binder, C; Calabro, Steve; Langhoff, Wayne; Chevrier, Marc
1Probity Research, Waterloo, Canada; 2University of Connecticut, Department of Dermatology, Farmington, United States; 3University of British Columbia, Department of Dermatology and Skin Science, Vancouver, Canada; 4Janssen Inc, Toronto, Canada; 5Janssen Services, LLC, Horsham, United States; 6Janssen Research & Development, LLC, Horsham, United States

P039 Genital involvement in Indian patients with psoriasis
Mathur, Sendhil Kumaran; Mahajan, Rahul; Dogra, Sunit; Narang, Tarun; Handa, Sanjeev
Postgraduate Institute of Medical Education and Research, Dermatology, Venerology, Leprology, Chandigarh, India

P040 Advanced Cardiometabolic Phenotyping in Psoriasis: Links Between Psoriasis and Cardiovascular Disease?
Mehra, Neha; Reilly, Murredich; Rader, Daniel; Mohamed, Emile; Van-Toorhees, Abby; Gelfand, Joel
1University of Pennsylvania, Cardiovascular Medicine, Philadelphia, United States; 2University of Pennsylvania, Dermatology, Philadelphia, United States

P041 Prevalence of doctor-diagnosed psoriasis and psoriatic arthritis in southern Sweden
Löfthandel, Sofia; Theander, Elke; Åke, Svensson; Martin, England; Aleksandras, Turkiewicz; Peterssson, Ingemar
1Clinical Sciences, Lund University, Lund, Dept. of Orthopedics, Lund, Sweden; 2Skåne University Hospital, Malmö, Dept. of Rheumatology, Malmö, Sweden; 3Skåne University Hospital, Malmö, Dept. of Dermatology, Malmö, Sweden

P042 Nail psoriasis: epidemiology and the burden of disease.
Klausen, Karin; Paxch, Marcel; von der Kerkhof, Peter
Radboud University Nijmegen Medical Centre, Dermatology, Nijmegen, Netherlands

P043 Comparative analysis of the cohorts with early and established Psoriatic Arthritis (PsA).
Khraishi, Majed; Aslanov, Rana
1NEXUS Clinical Research, St. John’s, Canada; 2Memorial University of Newfoundland, St. John’s, NL, Canada

P044 Biologic therapies in the treatment of psoriasis: their association with the development of specific inflammatory comorbid conditions among a cohort of the Newfoundland and Labrador population
Gulliver, Wayne; Gladney, Neil; Collins, Kayla; Morrissey, Andrea; MacDonald, Don
1Memorial University of Newfoundland, Faculty of Medicine, St. John’s, NL, Canada; 2Newfoundland and Labrador Centre for Health Information, St. John’s, NL, Canada
Abstract Titles continued

**P045** An examination of biologic treatment groups of psoriasis patients in a cohort of the Newfoundland and Labrador population

Gulliver, Wayne; Morrissey, Andrea; Gladney, Neil; Dowden, Jeffrey; Collins, Kayla; Alaghebandan, Reza; MacDonald, Don

1Memorial University of Newfoundland, Faculty of Medicine, St. John's, NL, Canada; 2Newfoundland and Labrador Centre for Health Information, St. John's, NL, Canada

**P046** PSOLAR: Canadian update of a multicentre, open registry of psoriasis patients

Poulin, Y; Bissonnette, R; Gulliver, W; Guenther, L; Lynde, C; Ho, V; Papp, Kim; Binder, C; Langhoff, Wayne; Chevrier, Marc

1Centre Dermatologique du Québec Métropolitain, Quebec City, Canada; 2Innovaderm, Montreal, Canada; 3Memorial University of Newfoundland, NewLab Clinical Research Inc; St. John's, Canada; 4Guenther Dermatology Research Centre, London, Canada; 5Lynde Dermatology, Markham, Canada; 6University of British Columbia, Department of Dermatology and Skin Science, Vancouver, Canada; 7Probiity Medical Research, Waterloo, Canada; 8Janssen Inc, Toronto, Canada; 9Janssen Services, LLC, Horsham, United States

**P047** Psoriatic Arthritis Mutilans in the Nordic countries; demographics and disease status

Gudbjörnsson, Björn; Leif, Eijstrup; Jan Tore, Gran; Lars, Iversen; Ulla, Lindqvist; Leena, Paimela; Thomas, Ternowitz; Mona, Ståhle

1University Hospital, Center for Rheumatology Research, Reykjavik, Iceland; 2Odense University Hospital, Department of Rheumatology, Odense, Denmark; 3Oslo University Hospitals, Department of Rheumatology, Oslo, Norway; 4Aarhus University Hospital, Department of Dermatology, Aarhus, Denmark; 5Uppsala University, Department of Medical Sciences, Uppsala, Sweden; 6Helsinki University Central Hospital, Department of Rheumatology, Helsinki, Finland; 7Stavanger University Hospital, Department of Dermatology, Stavanger, Norway; 8Dermatology Unit, Department of Medicine, Karolinska Institutet Stockholm, Stockholm, Sweden

**P048** Psoriasis- Epidemiology Characteristics and Patients’ Quality of Life; Palestine 2011

Nazzal, Zaher; Arda, Hisham; Elaf, Abuzarour

An-Najah National University, Nablus, Palestinian Territory

**P049** Natural course of psoriasis: A preliminary study

Alpayov, Erkan; Donmez, Levent; Nazlim, Berna; Otkesici, Birgal; Akman-Karakus, Ayse; Yilmaz, Erkan

1Akdeniz University, Dermatology and Venerology, Antalya, Turkey; 2Akdeniz University, Public Health, Antalya, Turkey

**P050** Childhood psoriasis: characteristics of the disease among Saudi population

Alajlan, Abdalmajeed; Alswaidan, Sami

1King Khalid University Hospital, Dermatology, KKH-Dermatology, Saudi Arabia; 2King Saud University, Dermatology, Riyadh, Saudi Arabia

Comorbidities

**P051** Atherosclerosis in patients with psoriasis: role of systemic inflammation

Yeung, Chi Keung; Yu, KH; Zhao, CT; Siu, CW; Tam, Sydney; Wong, CS; Yan, GH; Yue, WS; Khong, PL; Chan, Henry; Tse, HF

1The University of Hong Kong, Medicine, Hong Kong, Hong Kong; 2The University of Hong Kong, Clinical Biochemistry, Hong Kong, Hong Kong; 3The University of Hong Kong, Diagnostic Radiology, Hong Kong, Hong Kong

**P052** Considerations in the study of TNF-alpha inhibitor and methotrexate therapy on metabolic factors in psoriasis/ psoriatic arthritis and rheumatoid arthritis patients

Yu, Jiaxin; Rowan, Christopher; Poon, Kwan-Yee; Anthony, Mary; Xiang, Amy

1Kaiser Permanente Los Angeles Medical Center, Dermatology, Los Angeles, United States; 2Outcome, A Quintiles Company, Cambridge, United States; 3Kaiser Permanente Southern California, Department of Research and Evaluation, Pasadena, United States; 4Amen Inc., Center for Observational Research, Thousand Oaks, United States

**P053** Do TNF alpha-blockers influence male fertility?

Colsman, Andreas; Keieveliet, Franklin; Sticherling, Michael

Hauklinikk Universitätsklinikum Erlangen, Erlangen, Germany

**P054** Ophthalmic manifestations in psoriatic patients in a Brazilian referral center

Santos Paim de Oliveira, Maria de Fátima; de Oliveira Rocha, Bruno; Simon Yamakawa Boeira, Vanessa Lys; Abreu Azevedo Fraga, Nairara; Follador, Ivonise; Pedroira de Almeida Rêgo, Vitória Regina; de Oliveira- Chagas, Ricardo Danilo

1Federal University of Bahia, Dermatology, Salvador, Brazil; 2Federal University of Bahia, Ophthalmology, Salvador, Brazil

**P055** Vitamin D, body fat composition and parameters of atherogenesis and inflammation in psoriatic patients treated with narrow-band UVB

Romani, Jorge; Caixás, Assumpta; Ceperuelo, Victoria; Carrascoa, José M.; Ribera, Miquel; Rigla, Mercedes; Vendrell, Joan; Luelmo, Jesus

1Hospital Parc Taulí, Dermatology, Sabadell Barcelona, Spain; 2Hospital Parc Taulí, Endocrinology, Sabadell Barcelona, Spain; 3Hospital Joan XXIII, Endocrinology, Tarragona, Spain; 4Hospital Germans Trias i Pujol, Dermatology, Badalona, Spain

**P056** Adipocytokine expression and correlation with atherogenesis and inflammation markers in psoriatic patients treated with narrow-band UVB phototherapy

Romani, Jorge; Caixás, Assumpta; Ceperuelo, Victoria; Carrascoa, José M.; Ribera, Miquel; Rigla, Mercedes; Luelmo, Jesus

1Hospital Parc Taulí, Dermatology, Sabadell Barcelona, Spain; 2Hospital Parc Taulí, Endocrinology, Sabadell Barcelona, Spain; 3Hospital Joan XXIII, Endocrinology, Tarragona, Spain; 4Hospital Germans Trias i Pujol, Dermatology, Badalona, Spain

**P057** Prevalence of metabolic syndrome in psoriatic patients

RAVELLA MATEU, ANNA; Alhareda, M.; Castelló, M.; Saborit, S; Roqué, M; Peramiquel, L; Smandia, JA; Vila, LL

1HOSPITAL DOS DE MAIG, DERMATOLOGY, BARCELONA, Spain; 2Hospital Moises Broggi, Endocrinology, S. Joan Despi, Spain; 3Hospital Moises Broggi, Dermatology, S. Joan Despi, Spain; 4Moises Broggi, Endocrinology, S. Joan Despi, Spain

**P058** Use of brachial-ankle index for assessing cardiovascular risk in patients with psoriatic arthritis, psoriasis alone and controls: a pilot study

Magro-Checa, César; Rosales-Alexander, José Luis; Orgaz-Molina, Jacinto; Salvatierra, Juan; Arias-Santiago, Salvador; Cantero-Hinojosa, Jesús; Ruiz-Carrascosa, José Carlos; Raya-Álvarez, Enrique

1San Cecilio University Hospital, Rheumatology, Granada, Spain; 2San Cecilio University Hospital, Psoriasis Unit, Dermatology, Granada, Spain

**P059** Cardiovascular risk assessment in patients with psoriatic arthritis: comparison of european SCORE and two calibrated national guidelines

Magro-Checa, César; Rosales-Alexander, José Luis; Salvatierra, Juan; Cantero-Hinojosa, Jesús; Sánchez-Pareja, Ricardo; Montes-Garcia, Silvia; González-Dominguez, José; Raya-Álvarez, Enrique

San Cecilio University Hospital, Rheumatology, Granada, Spain
P061 Psoriasis and psoriatic arthritis: Large waist circumference and severity assessment
Kogan, Nora1; Gsuis, Simon1; Veira, Rosana1; Crespo, Alejandro1; Chaparro, Elena2; Amabile, Pilar2; Kreimer, Jennifer1; Castelli, Andrea1; Montoya, Sandra1; Kerzberg, Eduardo2
1Ramos Mejia Hospital, Dermatology, Buenos Aires, Argentina; 2Ramos Mejia Hospital, Rheumatology, Buenos Aires, Argentina

P062 Psoriasis and psoriatic arthritis: Body Mass Index and severity assessment
Kogan, Nora1; Gsuis, Simon1; Veira, Rosana1; Crespo, Alejandro1; Chaparro, Elena2; Amabile, Pilar2; Kreimer, Jennifer1; Castelli, Andrea1; Montoya, Sandra1; Kerzberg, Eduardo2
1Ramos Mejia Hospital, Dermatology, Buenos Aires, Argentina; 2Ramos Mejia Hospital, Rheumatology, Buenos Aires, Argentina

P063 Psoriasis and cardiovascular screening rates in the United States
Gustafson, Cheryl1; Alamdari, Habibollah; Davis, Scott; Huang, William; Feldman, Steve
Wake Forest University, Department of Dermatology, Winston-Salem, United States

P064 Association of renal cancer in a psoriasis cohort from the Newfoundland and Labrador founder population
Gulliver, Wayne1; Gladney, Neil1; Collins, Kayla1; Morrissey, Andrea2; MacDonald, Don1
1Memorial University of Newfoundland, Faculty of Medicine, St. John’s, NL, Canada; 2Newfoundland and Labrador Centre for Health Information, St. John’s, NL, Canada

P065 Risk of developing cancer among psoriasis patients as compared to non-psoriasis patients
Gulliver, Wayne1; Gladney, Neil1; Collins, Kayla1; Morrissey, Andrea2; MacDonald, Don1
1Memorial University of Newfoundland, Faculty of Medicine, St. John’s, NL, Canada; 2Newfoundland and Labrador Centre for Health Information, St. John’s, NL, Canada

P066 Association between pediatric psoriasis and the metabolic syndrome
Goldman, BA; Ari2; Au MD, Shiu-Chung2; Kim MD, Noori2; Loo MD, Daniel3; Dumont, Nicole1; Levine MD, Danielle1; Lizzul MD PhD MBA MPH, Paul1; Wolf MD, Eva1; Michelon MD, Melissa1; Wang MD, Andrew1; Tanis BA, Shmrat1; Kerensky MD, Todd1; Brown MD, Mary2; Kulig MD MPH, John1; Lopez-Benitez MD, Jorge1; Natter MD, Mark2; Miller MD, Laurie2; Pelajo MD MSc, Christina1; Davis MD, Trevor1; Gottlieb MD PhD, Alice3
1Tufts Medical Center, Dermatology, Boston, United States; 2Tufts Medical Center, Pediatrics, Boston, United States

P067 Coronary risk estimation and other cardiovascular comorbidities in moderate to severe psoriasis patients in Spain. RECOR study
Garcia-Culver, Carmen
Pfizer España, S.L.U, Medical Department, Madrid, Spain

P068 Association between systemic anti-psoriatic drugs and cardiovascular risk in patients with psoriasis and psoriatic arthritis: a nationwide cohort study
Chen, Yi-Ju1; Chang, Yun-Ting2; Shen, Jui-Lung1; Chen, Tsu-Ting2; Wang, Ching-Bi1; Chen, Chuan-Mei1; Wu, Chun-Ying2
1Taichung Veterans General Hospital, Department of Dermatology, Taichung, Taiwan; 2National Yang-Ming University, Taipei, Taiwan; 3Taichung Veterans General Hospital, Taichung, Taiwan, 4China Medical University, Taichung, Taiwan; 5National Chung-Hsing University, Taichung, Taiwan

P069 The use of ustekinumab in a patient with severe psoriasis and positive HBV serology
Steiglich, Raquel1; Carvalho, André VE1; Cheinquer, Hugo1; Meneghello, Luana1; Müller, Fernanda1
1Immandade da Santa Casa de Misericórdia de Porto Alegre, Dermatology, Porto Alegre, Brazil; 2Immandade da Santa Casa de Misericórdia de Porto Alegre, Hepatology, Porto Alegre, Brazil

P070 Prevalence of overweight/obesity in psoriasis population and its therapeutic consequences in clinical setting. Experience from Biobadaderm
Carrascosa, Jose-Manuel1; Vilavella, Marta1; Garcia-Doval, Ignacio1; Ferrandiz, Carlos1; Rivera, Raquel2; Carretero, Gregorio1; Dauden, Esteban3; Herrera, Enrique4; Alcina, Merce1; Ferran, Marta5; Lopez-Estebananz, Jose-Luis6; Gomez, Francisco7; Herranz, Jose-Manuel8; Vanacllocha, Francisco1; Biobadaderm, group13
1Hospital Universitari Germans trias i pujol, Dermatology, Badalona, Spain; 2Hospital Germans Trias i Pujol, Dermatology, Badalona, Spain; 3Unidad de Investigación Academia Española de Dermatologia, Madrid, Spain; 4Hospital 12 de Octubre, Dermatology, Madrid, Spain; 5Hospital Juan Negrin, Dermatology, Las Palmas, Spain; 6Hospital de la Princesa, Dermatology, Madrid, Spain; 7Hospital Universitario de Málaga, Dermatology, Málaga, Spain; 8Hospital Clinic y Provincial, Dermatology, Barcelona, Spain; 9Hospital del Mar, Dermatology, Barcelona, Spain; 10Hospital Infantia Leonor, Dermatology, Madrid, Spain; 11Hospital Universitario Reina Sofia, Dermatology, Cordoba, Spain; 12Hospital Alcorcon, Dermatology, Madrid, Spain; 13AEDV, Madrid, Spain

Current and new therapeutic modalities

P071 Management of severe cases of psoriasis: some interesting cases
XIAO, Ting
The First Affiliated Hospital of China Medical University, Dermatology, Shenyang, China

P072 Successful treatment of generalized pustular psoriasis in an 8 year old male with infliximab
Skrabl-Baumgartner, Andrea1; Salmofer, Wolfgang1; Muntean, Wolfgang2; Weser, Wolfgang²
1Medical University of Graz, Pediatric Department, Graz, Austria; 2Medical University of Graz, Department of Dermatology, Graz, Austria; 3MedicalUniversity of Graz, Pediatric Department, Graz, Austria

P073 A randomized, double-blind, placebo-controlled study of ustekinumab in Chinese patients with moderate to severe plaque psoriasis: LOTUS trial results
Zheng, M1; Zhu, X2; Song, M3; Shen, Y-K1; Wang, B2
1Second Affiliated Hospital, Zhejiang University School of Medicine, Dept of Dermatology, Hangzhou, China; 2Peking University First Hospital, Department of Dermatology and Venereology, Beijing, China; 3Janssen Research & Development LLC, Spring House, United States; 4Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing, China

P074 Efficacy and safety of secukinumab (a fully human anti-interleukin-17A antibody) in a phase II regimen-finding study for the treatment of moderate-to-severe plaque psoriasis
Rich, PA1; Sigurgeirsson, B1; Guettner, A1; Machacek, M1; Papavassilis, C1
1Oregon Dermatology and Research Center, Portland, United States; 2University of Iceland, Department of Dermatology, Reykjavik, Iceland; 3Novartis Pharma AG, Basel, Switzerland
P075 Recombinant bacterial system for local delivery of anti-TNFα biomolecules
Ravnikar, Matej1; Berlec, Ales2; Obermaier, Natasja3; Lunder, Mojca4; Strukelj, Borut5
1Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia; 2Jozef Stefan Institute, Ljubljana, Slovenia

P076 Psoriasis patients required to discontinue adalimumab therapy have worsening in their quality of life out of proportion to worsening in the objective signs of disease: subanalysis of REVEAL
Poulin, Yves1; Sheh, Pranav2; Gu, Yihua3; Okun, Martin4
1Centre Dermatologique du Québec Metropolitain, Québec, Canada; 2Eastern Virginia School of Medicine and Virginia Clinical Research, Inc., Norfolk, United States; 3Abbott Laboratories, Abbott Park, United States

P077 Phase IIa randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase (JAK) inhibitor, in patients with moderate-to-severe psoriasis
Papp, Kim1; Pariser, David2; Wierz, Gina3; Ball, Greg4; Akinlade, Bola5; Zeher, Bernhardt1
1Probyt Medical Research, East Waterloo, Canada; 2Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, United States; 3Astellas Pharma Global Development, Inc., Deerfield, United States

P078 Improvement of psoriasis in subjects with and without prior brodalumab (AMG 827) treatment in an open-label extension study
Papp, Kim1; Leonardi, Craig2; Menter, Alan3; Ortonne, Jean-Paul4; McInnes, Iain1; Sieper, Jürg1; Braun, Peter2; Emery, P3; van der Heijde, D4; Isaacs, P5; Dahmen, G6; Wollenhaupt, P7; Schulze-Koops, H8; Goteiger, S9; Bertolino, A.P.10; Hueber, W11; Tak, P.P.11
1University of Glasgow, Glasgow, United Kingdom; 2Charité’ Campus Benjamin Franklin, Berlin, Germany; 3Rheumazentrum Ruhrgebiet, Herne, Germany; 4University of Leeds, NIHR-LEeds Biomedical Research Unit and Leeds Institute of Molecular Medicine, Leeds, United Kingdom; 5Leiden University Medical Center, Leiden, Netherlands; 6Newcastle University and the Freeman Hospital, Newcastle-upon-Tyne, United Kingdom; 7Praxis fuer klinische Studien, Hamburg, Germany; 8Elibeck Hospital, Hamburg, Germany; 9Klinikum Innenstadt der Ludwig-Maximilians-Universitat, Munich, Germany; 10Novartis Pharma AG, Basel, Switzerland; 11University of Amsterdam, Amsterdam, Netherlands

P079 Long term efficacy and safety of ustekinumab in patients with moderate to severe psoriasis through 5 years of follow-up: results from the PHOENIX 1 long-term extension study
Papp, Kim1; Kimball, A2; Wasfi, Y; Chan, D3; Bissettone, R4; Sofen, H5; Yellding, N6; Li, S; Scapary, P7; Gordon, K8
1Probyt Medical Research, Waterloo ON, Canada; 2St Louis University, St Louis, United States; 3Baylor University Medical Center, Dallas, United States; 4Hospital de l’Archet, Nice, France; 5Amgen Inc, Thousand Oaks, United States

P080 Secukinumab for treatment of moderate-to-severe plaque psoriasis: results of a phase II dose-ranging study
Papp, K1; Sigurgeirsson, B2; Haemmerle, S3; Richards, H4; Papavassilis, C5
1Probyt Medical Research, Ontario, Canada; 2University of Iceland, Reykjavik, Iceland; 3Novartis Pharma AG, Basel, Switzerland

P081 Novel EPα antagonists as a new therapy for autoimmune diseases
Okumura, Takako1; Kanazawa, Kiyoshi2; Takahashi, Nobuyuki3; Take, Tukinori4
1RaQualia Pharma Inc., Research, Aichi, Japan

P082 Serendipity opens new avenues; A pilot study to evaluate the efficacy of saxagliptin in combination with cyclosporine and acitretin in diabetic psoriasis patients
Narang, Tarun1; Dogra, Sunil2; Handa, Sanjeev3
1Post Graduate Institute of Medical Education and Research, Chandigarh, India; 2Post Graduate Institute of Medical Education and Research, Chandigarh, India, Dermatology, Venereology and Leprology, Chandigarh, India

P083 Secukinumab, a fully human anti-interleukin-17A antibody, improves signs and symptoms of psoriatic arthritis: A 24-week, double-blind, placebo-controlled, multicenter trial
Melenes, J1; Sieper, J2; Braun, P3; Emery, P4; van der Heijde, D5; Isaacs, P6; Dahmen, G7; Wollenhaupt, P8; Schulze-Koops, H9; Goteiger, S10; Bertolino, A.P.11; Hueber, W12; Tak, P.P.13
1University of Glasgow, Glasgow, United Kingdom; 2Charité’ Campus Benjamin Franklin, Berlin, Germany; 3Rheumazentrum Ruhrgebiet, Herne, Germany; 4University of Leeds, NIHR-LEeds Biomedical Research Unit and Leeds Institute of Molecular Medicine, Leeds, United Kingdom; 5Leiden University Medical Center, Leiden, Netherlands; 6Newcastle University and the Freeman Hospital, Newcastle-upon-Tyne, United Kingdom; 7Praxis fuer klinische Studien, Hamburg, Germany; 8Elibeck Hospital, Hamburg, Germany; 9Klinikum Innenstadt der Ludwig-Maximilians-Universitat, Munich, Germany; 10Novartis Pharma AG, Basel, Switzerland; 11University of Amsterdam, Amsterdam, Netherlands

P084 Combined treatment of psoriasis with methotrexate and narrowband UVB phototherapy compared with methotrexate alone and narrowband UVB alone
Mashhadani, Sabeeh1; Al-Hamamy, Haider2; Nazar, Ihsan3
1College of Medicine/Baghdad University, Dermatology, Baghdad, Iraq; 2Department of Dermatology, University of Jordan, Amman, Jordan; 3Department of Dermatology, American University of Jordan, Amman, Jordan

P085 Treatment in mono-oligo- and polyarthritic patients; a 5 year study on the Swedish early psoriatic arthritis cohort (SwePSA)
Lindqvist, Ulla Ruth Kristina1; Husmark, Tomas2; Atelius, Gerd-Marie3; Larsson, P T4; Telemen, Anna5; Geijer, Mats6; Theander, E7
1Department of Medical Sciences, Rheumatology, Uppsala, Sweden; 2Department of Rheumatology, Falu Hospital, Falun, Sweden; 3Dept of Public Health and Clinical Medicine, Rheumatology, University of Umeå, Umeå, Sweden; 4Department of Rheumatology, Karolinska University Hospital Huddinge, Huddinge, Sweden; 5Spenshult Hospital, Oskarström, Sweden; 6Center of medical imaging and physiology, Lund University, Lund, Sweden; 7Department of Rheumatology, Skåne University Hospital, Malmö, Sweden

P086 Content validity of a novel patient-reported psoriasis symptom diary for patients with moderate-to-severe plaque psoriasis
Lebwohl, Mark1; Neryrady, F2; Gwillney, C.J.3; Strober, B.E.4
1The Mount Sinai School of Medicine, New York, United States; 2Novartis Pharmaceuticals Corporation, East Hanover, United States; 3PRO Consulting, Pittsburgh, United States; 4University of Connecticut, Farmington, United States

P087 Safety and efficacy of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis
Lebwohl, Mark G1; Kircik, Leon2; Callis Duffin, Kristina3; Pariser, David4; Hooper, Michele5; Henkert, Deborah6; Thompson, Elizabeth7; Yang, Jun8; John, Koo9
1Mount Sinai Medical Center, New York, NY, United States; 2Derm Research, PLLC, Louisville, KY, United States; 3University of Utah, Salt Lake City, UT, United States; 4Virginia Clinical Research, Inc., Norfolk, VA, United States; 5Amgen Inc, Thousand Oaks, CA, United States; 6University of California at San Francisco, San Francisco, CA, United States
P088 Secukinumab for treatment of moderate-to-severe plaque psoriasis: Results of a double-blind, parallel-group, placebo-controlled, phase II dose ranging study

Kumar, Nishi
Novartis, Hyderabad, India

P089 Our experience with naphtalan therapy in danish psoriasis patients

Krejci, Per; Gerdang1; Pasic, Aida2; Ceovic, Romana3; Stanimirovic, Andrijia4; Ivkovic, Jakov4; Ceovic, Romana4
1Naftalan, Special Hospital for Medical rehabilitation, Ivanic - Grad, Croatia; 2Zagreb University Hospital Center, Dermatology and Venerology, Zagreb, Croatia; 3School of Health Studies, Zagreb, Croatia

P090 Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate to severe palmoplantar psoriasis

Kim, MD; Noorai; An MD, Shi-Chung; Goldmz, Ari; Dumont, Nicole; Michelon MD, Melissa; Vol MD, Eva; Hession MD, Megan; Lizzul MD PhD MBA MPH, Paul; Andrews MD, Israel; Kereszy MD, Todd; Wang MD, Andrew; Yaniv; Shimrat; Gottlieb MD PhD, Alice
Tufts Medical Center, Dermatology, Boston, United States

P091 Ustekinumab in patients with active psoriatic arthritis: results of the phase 3, multicenter, double-blind, placebo-controlled SUMMIT I study

McInnes, I.F.; Kannawa, A.; Gottlieb, A.; Puig, I.; Rahman, P.; Ritchlin, C.; Li, S.; Wang, Y.; Mendelsohn, A.; Doyle, M.
1University of Glasgow, Glasgow, United Kingdom; 2University of California-San Diego, La Jolla, United States; 3Tufts Medical Center, Boston, United States; 4Universitat Autònoma de Barcelona, Barcelona, Spain; 5Memorial University, Newfoundland, Canada; 6University of Rochester, Rochester, United States; 7Janssen Research & Development, LLC, Spring House, United States; 8Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, United States

P093 ASP015K: A novel JAK inhibitor demonstrated potent efficacy in a chronic oxazolone-induced dermatitis model in rats

Higashi, Yasuyuki1; Inami, Masamichi2; Ito, Misato3; Chida, Noboru4; Nakanishi, Tomonori5; Ooshima, Shinsuke6; Hanawka, Koosri7; Okubo, Keiko8; Shirakami, Shosho9; Inoue, Takeyuki10; Fujii, Yasutomo11; Yamazaki, Shunji12
1Pharmacology Research Labs, Astellas Pharma Inc., Ibaraki, Japan; 2Astellas Research Institute of America LLC, Skokie, United States; 3Astellas Research Technology Co., Ltd., Osaka, Japan; 4Chemistry Research Labs, Astellas Pharma Inc., Ibaraki, Japan; 5Applied Pharmacology Research Labs, Astellas Pharma Inc., Ibaraki, Japan

P094 Efficacy and safety of topical combination treatments in chronic plaque psoriasis: A systematic literature review

Hendriks, Anke; Keijzers, Romy; de Jong, Elke; Seyger, Marieke; van de Kerkhof, Peter
Radboud University Nijmegen Medical Centre, Dermatology, Nijmegen, the Netherlands

P095 Psoriasis treatment expectations and healthcare provider relationships for patients in Europe, the USA and Canada

Hansen, Mikkel1; Bewley, Anthony2; Ersser, Steven; Ward, Corinne3
1LEO Pharma A/S, Corporate Medical Affairs, Ballerup, Denmark; 2Whips Cross University Hospital, Dermatology Service, London, United Kingdom; 3University of Hull, Faculty of Health and Social Care, Hull, United Kingdom; 4Mater Dei Hospital, Administration Department, Msida, Malta

P096 Use of modern psychometric techniques to demonstrate improvement in fatigue in RA patients treated with secukinumab

Gnanasakthy, A.; Bosko, M.; Durez, P.; Mallya, U.G.; Mpofu, S.
1Novartis Pharmaceuticals Corporation, East Hanover, United States; 2Quality Metric Incorporated, Lincoln, RI, United States; 3Université Catholique de Louvain, Brussels, Belgium; 4Novartis Pharma AG, Basel, Switzerland

P097 Association between reduction in disease activity, pain severity and health-related quality of life (HRQoL) among rheumatoid arthritis (RA) patients treated with secukinumab

Gnanasakthy, A.; Kosinski, M.; Genoves, M.; Mallya, U.G.; Mpofu, S.
1Novartis Pharmaceuticals Corporation, East Hanover, United States; 2Quality Metric Incorporated, Lincoln, RI, United States; 3Stanford University School of Medicine, California, United States; 4Novartis Pharma AG, Basel, Switzerland

P098 Evaluation of high and low intensity physical functioning in secukinumab treated RA patients: an application of IRT methodology

Gnanasakthy, A.; Kosinski, M.; Kellner, H.; Mallya, U.G.; Mpofu, S.
1Novartis Pharmaceuticals Corporation, East Hanover, United States; 2QualityMetric Incorporated, Lincoln, United States; 3Praxis München Nymphenburg, Germany, Germany; 4Novartis Pharma AG, Basel, Switzerland

P100 Etanercept in psoriasis and psoriatic arthritis: an Indian experience

Ghosh, Sanjay; Prasad, Balaram
1GM Medical College & LSK Hospital, Department of Dermatology, Kishanganj, India; 2Institute of Allergic & Immunologic Skin Diseases, Department of Dermatology & Internal Medicine, Kolkata, India

P101 Secukinumab improves signs and symptoms in patients with active rheumatoid arthritis: results of dose-finding, double blind, randomized, placebo controlled, phase II study

Genoves, Mark1; Durez, Patrick2; Richards, Hannah3; Supronik, Jerzy4; Dokoupioiva, Eva2; Aelton, Jacob A.5; Lee, Sung-Heon6; Coddimg, Christine E.7; Kellner, Herbert8; Ikawa, Takashi9; Hugot, Sophie10; Ligozio, Gregory11; Mpofu, Shephard12
1Stanford University, Palo Alto, Canada; 2University’s Catholique de Louvain, Brussels, Belgium; 3Novartis Pharma AG, Basel, Switzerland; 4NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; 5Medical Plus s.r.o, Uherske Hradiste, Czech Republic; 6Arthritis Clinic, Jackson, Tanzania; 7Konkuk University Medical Center, Seoul, Republic of Korea; 8Health Research of Oklahoma, Oklahoma, United States; 9Centre for Inflammatory Joint Diseases, Munich, Germany; 10Kobe–Konan Yamate Clinic, Kobe, Japan; 11Novartis Pharmaceuticals Corporation, East Hanover, United States

P102 Effect of secukinumab treatment on ACR50, HAQ-DI and EULAR remission rates in patients with Rheumatoid Arthritis

Genoves, Mark1; Kellner, Herbert1; Durez, Patrick1; Coddimg, Christine E.1; Ligozio, Gregory1; Richards, Hannah B.2; Escrig, Cesar3; Mpofu, Shephard4
1Stanford University, Palo Alto, United States; 2Centre for Inflammatory Joint Diseases, Munich, Germany; 3Université Catholique de Louvain, Brussels, Belgium; 4Health Research of Oklahoma, Oklahoma City, United States; 5Novartis Pharmaceuticals Corporation, East Hanover, United States; 6Novartis Pharma AG, Basel, Switzerland

P103 Maintenance therapy of psoriasis with cyclosporine: comparison between continuous and weekend therapy

Fernandes, Iolanda1; Torres, Tiago2; Selores, Manuel3
1Centro Hospitalar do Porto - Hospital de Santo António, Dermatology, Porto, Portugal; 2Centro Hospitalar do Porto - Hospital de Santo António, Porto, Portugal
P104 Formulation of anthralin in liquid solution for the treatment of scalp psoriasis

Farshi, Susan1; Farshi, Hooman2; Saghazadeh, Mojgan3

1Tehran University of Medical Sciences, Dermatology, Tehran, Islamic Republic of Iran; 2Azad University, Chemistry, Tehran, Islamic Republic of Iran; 3Qom Branch, Islamic Azad University, Microbiology, Tehran, Islamic Republic of Iran

P105 Secukinumab induces higher assessment of spondyloarthrits international society responses over placebo in patients with moderate-to-severe ankylosing spondylitis: results of 28-week, double-blind, randomized, placebo-controlled trial

Emery, Paul1; Baeten, D2; Sieper, J1; Braun, J; van der Heijde, D3; McInnes, I; van Laar, J; Landewe, R; Wordsworth, P; Wollenhaupt, J; Kellner, H; Paramarta, J; Bertolino, A; Gsteiger, S; Wright, A; Hueber, W

1University of Leeds, Department of Medicine, Leeds, United Kingdom; 2University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands; 3Charité Campus Benjamin Franklin, Department of Gastroenterology, Berlin, Germany; 4Rheumazentrum Ruhrgebiet, Department of Medicine, Herne, Germany; 5Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands; 6University of Glasgow, Glasgow Biomedical Research Centre, Glasgow, United Kingdom; 7Newcastle University, Department of Medicine, Newcastle upon Tyne, United Kingdom; 8Maastricht University Medical Center, Department of Medicine, Maastricht, Netherlands; 9Nuffield Orthopaedic Centre, Department of Medicine, Oxford, United Kingdom; 10Eli Beck Hospital, Hamburg, Klinik für Rheumatologie, Hamburg, Germany; 11Centre for Inflammatory Joint Diseases, Department of Medicine, Munich, Germany; 12Novartis Institutes for Biomedical Research, TM Dermatology, Basel, Switzerland; 13Novartis Pharma AG, Basel, Switzerland

P106 Secukinumab treatment has no effect on the lipid profile in patients with rheumatoid arthritis: results from a randomized, double-blind, placebo-controlled, phase II study

Durez, Patrick1; Genovese, M; Kellner, H; Coddin, C; Ligozio, G; Richards, R; Escrig, C; Mofj, S

1Cliniques Universitaires Saint-Luc, Tour Pasteur, Belgium; 2Stanford University, California, United States; 3Centre for Inflammatory Joint Diseases, Munich, Germany; 4Health Research of Oklahoma, Oklahoma, United States; 5Novartis Pharmaceuticals Corporation, East Hanover, United States; 6Novartis Pharma AG, Basel, Switzerland

P107 Phototherapy of psoriasis in the era of biologics: our experience

Crevic, Romana1; Kostovic, Kresimir; Bukić Mokos, Zrinka; Stulhofer Bukvic Mokos, Zrinka; 2St. Vincent's University Hospital, Rheumatology, Dublin, Ireland; 3Medical and Health Science Centre University of Debrecen, Laboratory Medicine, Debrecen, Hungary; 4Medical and Health Science Centre University of Debrecen, Rheumatology, Debrecen, Hungary

P108 Utilization of narrow-band UVB light therapy and Etanercept for the treatment of psoriasis/characteristics of PASI responders

Belouz, Monica

Hospital Nacional De Clinicas, Cordoba, Argentina

P109 Secukinumab reduces spinal inflammation as early as week 6 in patients with ankylosing spondylitis, as detected by magnetic resonance imaging – results of a double-blind, placebo-controlled, multicenter phase II proof-of-concept study

Baraliakos, X1; Braun, J; Laurent, D2; Baeten, D; van der Heijde, D3; Sieper, J; Emery, P; McInnes, I; van Laar, J; Landewe, R; Wordsworth, P; Wollenhaupt, J; Kellner, H; Wright, M; Gsteiger, S; Hueber, W

1Rheumazentrum Ruhrgebiet, Herne, Germany; 2Novartis Institutes for Biomedical Research, Basel, Switzerland; 3Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; 4Leiden University Medical Center, Leiden, Netherlands; 5Charite Campus Benjamin Frank- lin, Berlin, Germany; 6University of Leeds, Leeds, United Kingdom; 7University of Glasgow, Glasgow, United Kingdom; 8Newcastle University, Newcastle upon Tyne, United Kingdom; 9Maastricht University Medical Center, Maastricht, Netherlands; 10Nuffield Orthopaedic Centre, Oxford, United Kingdom; 11Eli Beck Hospital, Hamburg, Germany; 12Centre for Inflammatory Joint Diseases, Munich, Germany; 13Novartis Pharma AG, Basel, Switzerland

P111 Wnt pathway inhibitors in patients with psoriatic and rheumatoid arthritis treated with anti-TNF-α therapy

Svendsen, Agnete1; Bhatoo, Haujii Pa2; Antal-Szalmas, Peter3; Szekanecz, Zoltan4; Fitzgerald, Oliver

1St. Vincent’s University Hospital, Rheumatology, Dublin, Ireland; 2Medical and Health Science Centre University of Debrecen, Laboratory Medicine, Debrecen, Hungary; 3Medical and Health Science Centre University of Debrecen, Rheumatology, Debrecen, Hungary

P112 Serum IL-23 does not correlate with disease activity in psoriatic arthritis and SAPHO syndrome

Preziosa-Bedua, Hanno1; Brzosko, Iowa1; Fischer, Katarzyna; Brzosko, Marek

Pomeranian Medical University in Szczecin, Department of Rheumatology and Internal Diseases, Szczecin, Poland

P113 Molecular signature and new perspective markers of psoriasis

Melcev, Alexandra1; Sobolev, Vladimir2; Soboleva, Anna3; Bruskin, Sergey

1Institute of General Genetics, Functional Genomics, Moscow, Russian Federation; 2Institute of General Genetics, Functional Genetics, Moscow, Russian Federation

P114 Altered microRNA expression in peripheral blood mononuclear cells from patients with psoriasis

Loevendorf, Marianne B1; Zibert, John R; Marstrand, Troels2; Glue, Christian; Ødum, Niels1; Roepke, Mads A3; Skov, Lone

1LEO Pharma A/S, Molecular Biomedicine, Ballerup, Denmark; 2Exiqon A/S, Vedbaek, Denmark; 3University of Copenhagen, Department of International Health, Immunology & Microbiology, Faculty of Health Sciences, Copenhagen, Denmark; 4LEO Pharma A/S, Medical Department, Ballerup, Denmark; 5Gentofte Hospital, Dermato-allergology, Hellerup, Denmark

P115 Clinical examination versus magnetic resonance imaging of the hand and foot: its usefulness in early detection of psoriatic arthritis among patients with psoriasis

Korotayev, Tatiana1; Krasnenko, Svetlana2; Loginova, Elena3; Goryachev, Dmitriy4; Smirnov, Alexander

1Research Institute of Rheumatology, Laboratory of Seronegative Spondyloarthrits, Moscow, Russian Federation; 2Research Institute of Rheumatology, Radiology, Moscow, Russian Federation; 3Research Institute of Rheumatology, Laboratory of Medico-Social Investigations, Moscow, Russian Federation

P116 The relative activity of anti-TNF-α agents, etanercept, infliximab, adalimumab and golimumab, evaluated by a stable IL-8 reporter cell line, THP-G8

Kimura, Yutaka1; Takahashi, Toshiva; Yamashiki, Kensi; Aiba, Setsuya

Tohoku University Graduate School of Medicine, Department of Dermatology, Sendai, Japan

P117 Predictive biomarkers for high responsiveness to treatment, and biomarkers associated with clinical response to treatment , in psoriasis patients treated with the anti-IL-17A monoclonal antibody, ixekizumab

Hoffman, Robert1; Krueger, James1; Fretzin, Scott2; Dow, Ernst3; Nantz, Eric1; Komosar; Wendy1; Cameron, Gregory1; Phipps, Krista1; McColm, Juliet1; Banerjee, Subhashis

1Eli Lilly and Company, Indianapolis, United States; 2Rockefeller University, New York, United States; 3Dawes-Fretzin Dermatology Group, Indianapolis, United States
P118 The Swedish Early Psoriatic Arthritis (SwePsA) Registry 5-year follow-up: Slow radiographic progression of bone destruction in the hands without correlation to clinical disease activity
Gjer, Mats1; Lindqvist, Ulla2; Husmark, Tomas1; Alenius, Gerd-Marie3; Larsson, Per T4; Teleman, Anna1; Thander, Else1
1Skåne University Hospital, Lund, Center for Medical Imaging and Physiology, Lund, Sweden; 2Uppsala University, Rheumatology, Department of Medical Sciences, Uppsala, Sweden; 3Falun Hospital, Rheumatology, Falun, Sweden; 4Umeå University, Public Health and Clinical Medicine/Rheumatology, Umeå, Sweden; 5Karolinska University Hospital Huddinge, Rheumatology, Stockholm, Sweden; 6Spenshult AB, Oskarstrom, Sweden; 7Skåne University Hospital, Rheumatology, Malmö, Sweden

P119 A screening tool that includes key clinical features and biomarkers discriminates patients with psoriatic arthritis (PsA) from those with psoriasis without PsA
Chandrud, Vinod1; Cook, Richard2; Lee, Ker-Al3; Pellett, Fawnda1; Gladman, Dafna1
1Toronto Western Hospital, Division of Rheumatology, Toronto, Canada; 2University of Waterloo, Department of Statistics and Actuarial Science, Waterloo, Canada

P120 Treg profile of psoriasis patients - preliminary data
Boca, Andreu1; Tataru, Alexandru2; Orasan, Remus; Krauss, Tibor; Bucsaianu, Anca
University of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania, Cluj-Napoca, Romania

P121 Health-Related Quality Of Life (HRQOL) improvement with secukinumab in patients with rheumatoid arthritis: results from a dose-finding study
Vibeke, Strand4; Genoveses, M4; Mallya, UG5; Richards, H1; Mopoa, S1
1Stanford University, Division of Immunology/Rheumatology, Portola Valley, California; 2Stanford University School of Medicine, California, United States; 3Novartis Pharmaceuticals Corporation, East Hanover, United States; 4Novartis Pharma AG, Basel, Switzerland

P122 Use of clinical trial data to compare psoriasis area and severity index, static physician’s global assessment, and lattice system-physician’s global assessment in assessing severity of psoriasis
Tajasvi, Trilokraj1; Chow, Conroy2; Simpson, Matthew J3; Ellis, Charles N3
1University of Michigan Medical School, Department of Dermatology, Ann Arbor, Michigan, United States; 2University of Michigan School of Public Health, Department of Epidemiology, Ann Arbor, Michigan, United States

P123 Psychiatric disorders in psoriatic patients in Semnian city during the first six months of 2006: a survey.
Tahezi, Ramiz1; Behnam, Behnaz1
1Fatemie hospital/Semnian University of Medical Science, Internal Medicine, Semnan, Islamic Republic of Iran; 2Fatemie hospital/Semnan University of Medical Science, Psychiatry, Semnan, Islamic Republic of Iran

P125 Significant effects of patient educative training on psoriasis disease
Kling, Heidrun1; Jahn, Julia; Sticherling, Michael
Hautklinik Universitätsklinikum Erlangen, Erlangen, Germany

P126 Percentage of suicidal ideation and suicidal attempts in adult patients diagnosed with psoriasis
Siston, Antonio1; Verallo-Rowell, Vermén
Skin and Cancer Foundation, Inc, Dermatology, Pasig City, Philippines

P127 A descriptive study on the knowledge and beliefs of adult patients diagnosed with psoriasis
Siston, Antonio1; Verallo-Rowell, Vermén
Skin and Cancer Foundation, Inc, Dermatology, Pasig City, Philippines

P128 Quality of life and health-state utilities in psoriasis patients
Pan, Jian Yi1; Theng, Colin; Tan, Suat Hoon
National Skin Centre, Singapore

P129 The psoriatic school, education for patients with psoriasis, psoriatic arthritis and pustulosis palmoplantaris
Naslund, Anna1; Stymne, Birgitta2; Stenerquist, Anne3
1The Swedish Psoriasis Association, Stockholm, Sweden; 2University Hospital Linkoping, Dermatology department, Linkoping, Sweden

P130 Perceived disadvantages in leisure time activities among patients with psoriasis
Leino, M4; Mattila, K1; Mustonen, A1; Koulu, L1; Tuominen, R1
1Turku University Hospital, Dermatology, Turku, Finland; 2University of Turku, Public Health, Turku, Finland

P131 Quality-of-life effects of psoriasis skin symptoms affecting different body regions
Kimball, Alexa B1; Sundaram, Murali2; Signorovitch, James1; Yang, Min3; Mulani, Parvez M3
1Harvard Medical School, Department of Dermatology, Boston, MA, United States; 2Abbott Laboratories, Global Health Economics and Outcomes Research, Abbott Park, IL, United States; 3Analysis Group, Inc., Boston, MA, United States

P132 The use of an Apple iPad-based© Health Assessment Questionnaire (HAQ) application in psoriatic and rheumatoid arthritis
Khraishi, Majed1; Aslanov, Rana2
Newfoundland Labrador Research Technologies, St. John’s, Canada

P133 Psoriasis - a model for chronic diseases in dermatology
Gupta, Monica1; Gupta, Monisha2
1Skin and Cancer Foundation Australia, NSW, Strathfield, Australia; 2Skin and Cancer Foundation Australia, NSW, Darlinghurst, Australia

P134 Association between ACR improvement and health-related quality of life (HRQoL) among rheumatoid arthritis (RA) patients treated with secukinumab
Gnanasambantham, A1; Kosinski, M2; Genoveses, M1; Mallya, UG3; Mopoa, S1
1Novartis Pharmaceuticals Corporation, East Hanover, United States; 2QualityMetric Incorporated, Lincoln, United States; 3Stanford University School of Medicine, California, United States; 4Novartis Pharma AG, Basel, Switzerland

P135 Sex-specific differences in health-related quality of life in patients with moderate to severe psoriasis
Cather, Jennifer C1; Horn, Elizabeth J2; Sundaram, Murali3; Bao, Yanjun1
1Modern Dermatology, a Baylor Health Texas Affiliate, and Modern Research Associates, Dallas, TX, United States; 2Modern Research Associates, Dallas, TX, United States; 3Abbott Laboratories, Global Health Economics and Outcomes Research, Abbott Park, IL, United States

P136 Sex differences in health-related quality of life in patients with moderate to severe psoriasis
Cather, Jennifer C1; Horn, Elizabeth J2; Sundaram, Murali3; Yang, Min3; Farooqui, Saif4; Mulani, Parvez M3
1Modern Dermatology, a Baylor Health Texas Affiliate, and Modern Research Associates, Dallas, Texas, United States; 2Modern Research Associates, Dallas, Texas, United States; 3Abbott Laboratories, Global Health Economics and Outcomes Research, Abbott Park, IL, United States; 4Analysis Group, Inc., Boston, MA, United States
Abstract Titles continued

P137  Colors of psoriasis: The lived experiences of middle aged adults with moderate to severe psoriasis

Susan Kiel Lara1; Caballes, Ana Angela2; Caboboy, Jessica Louise3; Maravilla, Susan4
1University of Santo Tomas, Manila, Nursing, Angeles city, Philippines; 2University of Santo Tomas, Manila, Nursing, Manila, Philippines; 3University of Santo Tomas, Manila, Nursing, Novaliches, Philippines; 4University of Santo Tomas, Manila, Nursing, Quezon, Manila, Philippines

P138  The global challenge of stigmatization and discrimination for people with psoriasis: Preliminary results of a survey carried out by the International Federation of Psoriasis Associations and 15 national member associations

Bohanan, Barbra1; Gallant, Kathleen2
1IFPA, Stockholm, Sweden; 2IFPA Executive Committee/Chair of IFPA Task Force on NCDs Committee, Pittsburgh, United States

P139  Psoriasis Uncovered: The results of two quantitative surveys of psoriasis patients in Australia

Baker, Christopher; Foley, Peter; Braue, Anna
Skin and Cancer Foundation Inc, Carlton, Australia

P140  Erectile dysfunction: a rare side effect of methotrexate

Yaylı, Savadjı; Akın, Burak; Aksu Arıça, Deniz; Bahadır, Sevgı
Karadeniz Technical University School of Medicine, Department of Dermatology, Trabzon, Turkey

P141  Anti-TNF-alpha treatment in a psoriatic patient with concurrent HCV infection

Santos Paim de Oliveira, Maria de Fátima; de Oliveira Rocha, Bruno; Follador, Ivonise; Pedreira de Almeida Rêgo, Vitória Regina
Federal University of Bahia, Dermatology, Salvador, Brazil

P142  Tinea capitis in two sisters of a “wooly hair” family

Ozturk, Kemal1; Ozturk, Perihan2; Karakas, Tugba3; Dokur, Neslihan
KSU Medicine Faculty, Dermatology, Kahramanmaras, Turkey

P143  Concurrent of progressive macular hypomelanosis and port-wine stain nevus in the same patient

Ozturk, Perihan1; Ozturk, Kemal2; Dokur, Neslihan3
KSU Medicine Faculty, Dermatology, Kahramanmaras, Turkey

P144  Together of progressive macular hypomelanosis and port-wine stain nevus in the same patient

Ozturk, Perihan1; Ozturk, Kemal2; Dokur, Neslihan3
KSU Medicine Faculty, Dermatology, Kahramanmaras, Turkey

P145  A case of multiple cutaneous leismaniasis cured with intramuscular sodium stibogluconate

Ozturk, Perihan1; Ozturk, Kemal2; Dokur, Neslihan3; Karakas, Tugba
KSU Medicine Faculty, Dermatology, Kahramanmaras, Turkey

P146  Successful treatment of a paradoxical palmoplantar pustulosis with ustekinumab in a patient with psoriatic arthritis

Morales Manera, Caridad Elena1; López Ferrer, Anna2; Puig Sanz, Luis3
Hospital la Santa Creu i Sant Pau, Dermatology, Barcelona, Spain

P147  Annular pustular psoriasis in a patient with pemphigus foliaceus

Kato, Kenichi1; Totsumi, Motohiro2; Takahashi, Yuji3; Yamanaka, Takashi
Kansai Rosai Hospital, Department of Dermatology, Amagasaki city, Hyogo Prefecture, Japan

P148  Psoriatic arthritis and Degos diseases: a clinical case

Landoh, Rafael1
S. G. Moscati Hospital, Dermatology, Avellino, Italy

P149  Coexisting of psoriasis and lupus erythematosus: A diagnostic and therapeutic challenges

Elsherif, Nada A1; Elmatardi, Marada A2; Eldahsuni, Aklam S1; Elmanageh, Ibisis M1
1Benghazi university, dermatology department, Benghazi, Libyan Arab Jamahiriya; 2Jamhoria hospital, dermatology department, Benghazi, Libyan Arab Jamahiriya

P150  Successful treatment of a patient with undifferentiated connective tissue disease and psoriasis with ustekinumab

Brown-Maher, Tracey1; Astani, Roxanna2; Galliver, Wayne
Memorial University of Newfoundland, Faculty of Medicine, St. John’s, NL, Canada

P151  Cost of psoriasis and psoriatic arthritis in Denmark

Setterstrom, Riara1; Gniadecki, Robert2; Kragballe, Knud1; Zachariae, Claus3; Lindkvist, Rose-Marie4; Qvitzau, Susanne5; Olsen, Jens6
1University of Southern Denmark, Centre for Applied Health Research and Technology Assessment (CAST), Odense, Denmark; 2Bispebjerg Hospital, Department of Dermatology, Copenhagen, Denmark; 3Aarhus University Hospital, Department of Dermatology, Aarhus, Denmark; 4Gentofte Hospital, Department of Dermatology, Copenhagen, Denmark; 5Pfizer, Medical and Access, Ballerup, Denmark; 6Pfizer, Medical, Ballerup, Denmark

P152  One-year cost-effectiveness analysis of etanercept vs. adalimumab for moderate-to-severe plaque psoriasis

Ruano, Juan1; Isla-Tijera, Beatriz1; Jiménez-Paya, Rafael2; Cárdenas, Manuel3; Gómez, Francisco1; Vezes García-Nieto, Antonio4; Del Prado-Llergo, Jose-Ramón5; Moreno-Giménez, José-Carlos6
1Reina Sofia University Hospital, Department of Dermatology, Córdoba, Spain; 2University Hospital, Department of Pharmacy, Córdoba, Spain

P153  Impact of psoriasis on work performance

Mattila, Kalle1; Leino, Mauri2; Koulu, Leena1; Tuominen, Risto3
1University Hospital, Turku, Dermatology, Turku, Finland; 2University of Turku, Department of Public Health, Turku, Finland

P154  Important of psoriasis severity index in social-medical expertise

Chiavedez, Nino1; Tsuqarreichvili, Konstantine2; Datuashvili, Maia3
1Psoriasis Association of Georgia - PSO Georgia, Dermatology, Kutaisi, Georgia; 2Psoriasis Association of Georgia - PSO Georgia, Kutaisi, Georgia

P155  Studying the calcium serum level in patients suffering from psoriasis

Goldast, Mohamad
Tabriz University of medical sciences, Tabriz, Islamic Republic of Iran
FOR 125 MILLION PEOPLE - HERE’S HOPE!

THANK YOU FOR JOINING US FOR THE 3RD WORLD PSORIASIS & PSORIATIC ARTHRITIS CONFERENCE AND FOR ALL YOUR HARD WORK AND EFFORTS TOWARD HELPING PEOPLE WITH PSORIASIS ALL OVER THE WORLD!

Learn more about IFPA and our projects on www.ifpa-pso.org.
We are pleased to be the official airline network for this event and we hope your participation in the 3rd World Psoriasis & Psoriatic Arthritis Conference 2012 is a successful one.

Here are some opportunities to join us!

Visit our website (www.eadv.org) for further information

THE STAR ALLIANCE NETWORK WELCOMES YOU TO STOCKHOLM

We are pleased to be the official airline network for this event and we hope your participation in the 3rd World Psoriasis & Psoriatic Arthritis Conference 2012 is a successful one.

staralliance.com
The 3rd World Psoriasis & Psoriatic Arthritis Conference 2012 is presented by the International Federation of Psoriasis Associations, IFPA

and supported by

Official airline

SAS

STAR ALLIANCE
THE WAY THE EARTH CONNECTS
Welcome to IFPA

Worldwide unity for people living with psoriasis